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4.  Introduction 
4.1 Hypertension 
4.1.1 Epidemiology and classification 
Hypertension as in “high tension” and “high blood pressure” is a disease affecting billions of 
people worldwide. Essential hypertension can be defined as a rise in blood pressure of 
unknown cause that increases the risk for cerebral, cardiac, and renal events1. In a recent 
review the lifetime risk of becoming hypertensive in industrialised countries was estimated to 
exceed 90%1. Historically more emphasis was placed on diastolic than on systolic blood 
pressure as a predictor of cardiovascular morbidity and mortality2, and systolic blood pressure 
limits was not included in early guidelines and hypertension trials. In recent years more 
emphasis has been on the observation that in especially elderly people the risk of morbidity 
and mortality is directly proportional to the systolic blood pressure and the pulse pressure 
(systolic blood pressure minus diastolic blood pressure)3. In a large meta-analysis of 
observational data from 61 studies in almost 1 million subjects without cardiovascular disease, 
both systolic and diastolic blood pressures were independently and similar predictive of 
vascular (and overall) mortality, without any evidence of a threshold down to at least 115/75 
mmHg4, and therefore risk assessment in current guidelines are based on both systolic and 
diastolic measurements3, 5-7.
According to the new European Guidelines from the European Society of 
Hypertension (ESH) and the European Society of Cardiology (ESC), hypertension is graded 
from 1-3 of values above 140/90 mmHg (Table 1)3. However, the real threshold for 
hypertension and treatment must be considered flexible, being higher or lower based on the 
total cardiovascular risk of each individual patient3.
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Table 1. Definitions and classification of blood pressure levels (mmHg) according to 
ESH/ESC 2007 guidelines3.
Category Systolic Blood Pressure  Diastolic Blood Pressure
Optimal <120 and <80 
Normal 120-129 and/or 80-84 
High normal 130-139 and/or 85-89 
Grade 1 hypertension 140-159 and/or 90-99 
Grade 2 hypertension 160-179 and/or 100-109 
Grade 3 hypertension 180 and/or 110 
Isolated systolic hypertension 140 and <90 
* When a patient’s systolic and diastolic blood pressures fall into different categories the higher category 
should be applied 
4.1.2 Pathophysiology
Hypertension is a disorder of mismatch between intravascular volume and vasoconstriction 
resulting in excessive wall stress that damages the blood vessels and organs. The pathogenesis 
of essential hypertension is incompletely understood, and involves complex interactions 
between genetic, environmental and demographic factors8. Major pathophysiological 
mechanisms include increased sympathetic nervous system (SNS) and renin-angiotensin-
aldosterone system (RAAS) activity9, but a variety of other neural, hormonal, vascular and 
metabolic factors are also involved. 
 The SNS and renin-angiotensin system (RAS) have both mutually reinforcing actions 
that combine to regulate blood pressure. Sympathetic drive increases renin secretion from the 
juxtaglomerular cells of the kidney, thereby exerting amplified effects on the RAS, and 
angiotensin II increases noradrenaline release from sympathetic nerve terminals and 
potentates the vasoconstrictor responses to noradrenaline9. Blood pressure is regulated in the 
long-term by adjusting blood volume through urinary sodium and water excretion by the 
kidneys10 and short-term regulation is exerted through hormones, mechanical factors and 
neural reflexes11. The arterial baroreceptors are mechanosensitive nerve endings sited in the 
carotid sinuses and the aortic arch and provide an important and powerful feedback 
mechanism of blood pressure regulation12. Although the pathophysiology may be complex, 
the result is an increase in blood pressure known to make organ damage and increase 
morbidity and mortality.  
4.1.3 Complications 
Hypertension has been called the “silent killer”13 as many do not experience any symptoms of 
the high blood pressure itself. However, the World Health Organization (WHO) has reported 
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high blood pressure as a leading cause of death worldwide14. Stroke has been labelled as the 
most important “hypertension related complication”2, 3 , but also coronary events, heart failure, 
peripheral artery disease and end stage renal disease are known as important hypertension 
related diseases. As patients with hypertension often exhibit additional cardiovascular risk 
factors like dyslipidaemia, glucose metabolism abnormalities, obesity or left ventricular 
hypertrophy15, the assessment of total cardiovascular risk is important when evaluating and 
treating these patients3.
4.1.4 Treatment 
Non-pharmacological treatment regimens like low salt diet, weight loss, exercise, and alcohol 
restriction have been shown in meta-analyses to lower blood pressure16-19. However, 
antihypertensive drugs often have to be used to reach the blood pressure target of below 
140/90 mmHg (or lower if high-risk patients).  Five major classes of antihypertensive agents 
are recommended according to recent guidelines, either in monotherapy or in suitable 
combinations; thiazide diuretics, calcium channel blockers (CCBs), angiotensin-converting 
enzyme inhibitors (ACEIs), angiotensin II-receptor blockers (ARBs) and beta-blockers3. Most 
patients require multiple drugs to achieve blood pressure targets, but unfortunately many 
patients still remain untreated or under-treated. 
4.2 Diabetes mellitus 
4.2.1 Epidemiology and classification 
The global number of individuals with diabetes mellitus in 2000 was estimated to be 171 
million (2.8% of the world’s population), but many patients are undiagnosed and the 
prevalence is increasing exponentially primarily because of increase in sedentary lifestyle and 
obesity20. The estimated lifetime risk of diabetes mellitus is 30-40%21, and as in most other 
countries in the world the prevalence of diabetes mellitus in Norway is also increasing22.
Diabetes mellitus is a metabolic disorder of multiple aetiology characterised by 
chronic hyperglycaemia with disturbances of carbohydrate, fat, and protein metabolism 
resulting from defects of insulin secretion, insulin action, or a combination of both23. It 
consists in two distinct forms; Type 1 which usually occurs in younger subjects and type 2 
which is far more common and comprising over 90% of adults with diabetes mellitus23.
There are different diagnostic criteria and different ways to classify dysglycaemia and 
diabetes mellitus, but the WHO 1999 criteria, as shown in Table 2, is often used24.
Progression from normal glucose tolerance to diabetes mellitus involves intermediate stages. 
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Impaired fasting glucose (IGF) and impaired glucose tolerance (IGT) are both known risk 
factors for later diabetes mellitus development25, but IGT is probably a stronger marker of 
future cardiovascular disease25-27.
Table 2. Criteria used for glucometabolic classification according to WHO 199923, 24
Glucometabolic category Classification criteria* 
Normal glucose regulation Fasting plasma glucose <6.1 mmol/L + 2-hour post-
load plasma glucose < 7.8 mmol/L†
Impaired fasting glucose (IFG) Fasting plasma glucose 6.1 mmol/L and <7.0 mmol/L 
+ 2-hour post-load plasma glucose <7.8 mmol/L†
Impaired glucose tolerance (IGT) Fasting plasma glucose < 7.0 mmol/L + 2-hour post-
load plasma glucose 7.8 mmol/L and <11.1 mmol/L†
Impaired glucose homeostasis Impaired fasting glucose or impaired glucose tolerance 
Diabetes mellitus Fasting plasma glucose 7.0 mmol/L or 2-hour post-
load plasma glucose 11.1 mmol/L†
* 1 mmol/L glucose= 18 mg/dL glucose 
† Standardised oral glucose tolerance test (OGTT); Performed in the morning, after an overnight fast         
(8-14 h); one blood sample should be taken before and one 120 min after intake of 75 g glucose dissolved in 
250-300 mL water in the course of 5 minutes 
4.2.2 Pathophysiology 
Hyperglycaemia results from insulin supply insufficient to meet the body's needs, and in 
diabetes mellitus the hyperglycaemia exceeds the threshold where the risk of diabetic 
retinopathy is currently thought to begin (Table 2)24. In type 1 diabetes mellitus there is a lack 
of pancreatic insulin production due to ȕ-cell destruction and an absolute insulin deficiency23.
While in type 2 diabetes mellitus there is a chronic and often progressive peripheral insulin 
resistance and an insufficient insulin supply due to increased demands and a relative insulin 
deficiency. These processes antedate the clinical diagnosis of diabetes mellitus, they cause the 
disease, and they continue to worsen after the diagnosis is made. The rising blood glucose in 
type 2 diabetes mellitus results from a combination of genetic predisposition, unhealthy diet 
of energy dense food, physical inactivity, and increasing weight with a central distribution 
resulting in complex pathophysiological processes23. In the following I will focus on type 2 
diabetes mellitus. 
4.2.3 Risk factors 
To qualify as a risk factor for diabetes mellitus, the association between the risk factor and the 
disease must be independent of known confounders and the evidence must suggest that 
interventions to reduce the risk factor (not always possible) will lead to a reduction in risk of 
diabetes mellitus25. Early detection and treatment of risk factors may decrease the chance of 
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developing diabetes mellitus and diabetes complications. The entity of risk factors named the 
metabolic syndrome, as discussed below, are known to increase the risk of developing type 2 
diabetes mellitus28.
Possibly, the most important risk factor for diabetes mellitus development may be 
genetics. A first-degree relative with diabetes mellitus is important when assessing a patient’s 
risk of developing diabetes mellitus. There are also high-risk populations and known 
differences in diabetic risk between races e.g. African Americans are known to have an 
elevated risk of diabetes mellitus compared with Caucasians29, 30. The risk for diabetes 
mellitus also increases with age31.
When looking at more modifiable risk factors, dysglycaemia and increased blood 
glucose are as expected important risk factors for diabetes development32. IFG as defined 
above is a known risk factor for diabetes mellitus33, but there is probably a continuum of 
increased risk from even lower levels of ”normal” fasting glucose. The results from the 
MELANY study showed that increased fasting glucose level from even within the normal 
range (<5.55 mmol/L) constitutes an independent risk factor for later type 2 diabetes mellitus 
development34. These results may suggest that there is a relative overproduction of hepatic 
glucose already existent in patients at risk of diabetes and in a retrospective analysis there has 
been shown that there is an elevated risk of cardiovascular disease (myocardial infarction and 
stroke) more than 15 years before the clinical diagnosis of diabetes mellitus35. Unhealthy diet, 
smoking, physical inactivity and obesity are other important modifiable risk factors for 
diabetes36. Some data have shown that waist circumference, as a measurement of obesity, 
predicts diabetes mellitus marginally better than body mass index (BMI)37-39, however other 
studies have shown equivalent predictive value38. Low socioeconomic status is also shown to 
be an important risk factor for diabetes mellitus31.
 Hypertension and diabetes mellitus often cluster together, and other cardiovascular 
diseases like peripheral vascular disease also increase the risk of diabetes development31, 40.
Blood pressure and blood pressure progression were strong and independent predictors of 
type 2 diabetes mellitus in The Women’s Health Study41. The multivariable adjusted hazard 
ratio (HR) was 2.03 (1.77-2.32) in patients with hypertension compared to patients with 
normal blood pressure (120-129/75-84 mmHg) after adjusting for BMI and other components 
of the metabolic syndrome41. This is in line with the results from the ARIC study showing a 
relative risk of developing diabetes mellitus of 2.34 (2.16-2.73) in hypertensives42.
 Different treatment regimens (e.g. diuretics, beta-blockers, and steroids) and other 
biochemical markers (e.g. dyslipidaemia, ALAT (alanine aminotransferase), and CRP (C 
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reactive protein)) have been linked with diabetes development, but the association may not be 
so general and independent.  
4.2.4 Complications 
Diabetes mellitus is associated with development of specific long-term organ damages 
including retinopathy, nephropathy and autonomic dysfunction23. These microvascular 
damages are related to the hyperglycaemia and the threshold for the diabetes diagnosis24.
Patients with diabetes mellitus are also at a particularly high risk for cardiovascular, 
cerebrovascular, and peripheral artery disease23, and these macrovascular diseases are with 
lesser degree associated with hyperglycaemia and the increased risk starts below the level of 
blood glucose used to define diabetes mellitus and before the actual diabetes mellitus 
diagnosis25, 43. More than 20% of patients admitted for suspected myocardial infarction have 
type 2 diabetes mellitus44. And a difference in morbidity and mortality between patients with 
and without diabetes mellitus has remained despite improved therapeutic modalities that have 
resulted in a decline in the overall morbidity and mortality following acute coronary artery 
disease45. Possible mechanisms may be diffuse coronary atherosclerosis, diabetic 
cardiomyopathy, autonomic neuropathy, increased heart rate, increased thrombus formation, 
or an impaired fibrinolytic function in diabetics44. In long-term follow-up studies it has been 
shown that patients with diabetes mellitus without any prior myocardial infarction have 
similar risk for fatal coronary heart disease as non-diabetic patients with prior myocardial 
infarction46-48. The majority of deaths in patients with diabetes mellitus result from 
accelerated cardiovascular and cerebrovascular atherosclerosis25, and cardiovascular mortality 
is increased 1.5-4.5-fold, and all-cause mortality is increased 1.5-2.7-fold in diabetics25. The 
combination of diabetes mellitus and hypertension may have especially ominous 
consequences and increases the risk of coronary heart disease independently and 
dramatically49, 50.
4.2.5 Treatment 
Type 2 diabetes is a progressive disease and prevention or treatment requires modification of 
the underlying condition and reduction of the hyperglycaemia. Lifestyle intervention is 
important and has shown to reduce the risk of developing diabetes in patients with IGT with 
almost 60%51, 52, and lifestyle intervention with diet and physical activity should be 
emphasised in all patients. Oral anti-diabetic drugs (e.g. acarbose, metformin, sulfonylurea, 
thiazolidinediones) may reduce hyperglycaemia due to reduced glucose absorption, increased 
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insulin sensitivity and increased insulin secretion. Many patients with type 2 diabetes mellitus 
may also need insulin treatment to get their diabetes under control. Aggressive management 
of other cardiovascular risk factors including hypertension and dyslipidaemia are also 
important and tight blood pressure control has shown to substantially decrease the risk of 
diabetes-related deaths and the progression of microvascular and macrovascular 
complications53, 54. Some antihypertensive treatment regimens has also shown potential to 
reduce or postpone diabetes development55, 56.
4.3 Insulin resistance 
In healthy subjects insulin action and secretion are coordinated to regulate the blood glucose 
level into normoglycaemia. The response to elevated plasma glucose is insulin secretion that 
stimulates glucose uptake and glycogen synthesis and inhibits glycogenolysis and 
gluconeogenesis in insulin responsive tissues (i.e. liver, fat and skeletal muscle). Skeletal 
muscle is the largest tissue by mass regulated by insulin and is responsible for more than 80% 
of insulin stimulated glucose disposal57. The glucose uptake in peripheral tissue is a complex 
mechanism. The activation of the glucose-transport system is highly regulated starting with 
insulin stimulation and via series of intracellular proteins resulting in translocation of the 
glucose transporter GLUT-4 to the sarcolemma membrane where glucose transport takes 
place via a facilitative diffusion process58. Glucose transport into muscle can also be 
stimulated by insulin-independent mechanisms activated by contraction and hypoxia, but less 
is known about these mechanisms58.
The term insulin resistance refers to reduced capacity of insulin to stimulate glucose 
uptake and utilisation, and is a primary defect leading to the development of pre-diabetes and 
overt type 2 diabetes mellitus58. In insulin resistance, intracellular defects in the insulin 
signalling sequence result in reduced GLUT-4 translocation and glucose uptake. Skeletal 
muscle accounts for a large part of insulin-stimulated glucose disposal and is the major site of 
peripheral insulin resistance. The aetiology of skeletal muscle insulin resistance is 
multifactorial, but accumulating evidence shows that over-activity of RAS is one important 
contributor58. Other mechanism like oxidative stress, SNS activity, and excessive visceral 
adipose tissue lipolysis or reduced adiponectin levels may also contribute59. A compensatory 
hyperinsulinaemia is thought to permit normal glucose tolerance as long as pancreatic ȕ-cell 
function is sufficient. 
A number of methods have been developed for the quantitative measurement of 
insulin sensitivity. The hyperinsulinaemic glucose clamp technique is considered to be the 
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most accurate or the “gold standard”60, but other methods like insulin infusion sensitivity test 
and different model assessments also exist61, 62.
Insulin resistance is associated with dyslipidaemia, hypertension, hypercoagulability 
and atherosclerosis. The link between insulin resistance and hypertension is not known for 
sure63, 64, as only about 50% of hypertensive subjects are insulin-resistant64.  Post-insulin-
receptor defects, altered skeletal muscle fibres and decreased skeletal muscle blood flow with 
reduced delivery of insulin and glucose may cause insulin resistance in hypertensives63.
Insulin resistance in hypertension appears to be strongly dependent of abdominal and overall 
obesity65, but not entirely66. According to the hypothesis of Landsberg67, insulin resistance in 
the obese is a mechanism evolved to limit further weight gain, and the price to pay is the 
hyperinsulinaemia and sympathetic activation which increase blood pressure through 
vasoconstriction, kidney sodium reabsorption and increased cardiac output. According to the 
hypothesis of Julius68, enhanced sympathetic activity is the primary factor to be associated 
with both hypertension, insulin resistance and possibly obesity. Sympathetic influences may 
reduce insulin sensitivity via haemodynamic effects due to vasoconstriction and increased 
diffusion target-distance or by direct cellular effects59. Insulin resistance can reciprocate 
sympathetic stimulation and sympathetic stimulation can cause insulin resistance, and a 
vicious cycle may evolve in which the components reinforce each other68 and a classic 
“chicken and egg” question is raised59.
4.4 The metabolic syndrome 
In 1988 Reaven described a syndrome designed “syndrome X” based on the clustering of the 
following abnormalities: resistance to insulin-stimulated glucose uptake, hyperinsulinaemia, 
hyperglycaemia, increased triglycerides, decreased high-density lipoprotein (HDL) 
cholesterol and high blood pressure69. The clustering had been known for decades70, but he 
proposed insulin resistance as the common feature and the aetiology of the syndrome. 
However, growing evidence suggests that several of the factors are primarily caused by 
obesity (especially intra-abdominal adiposity or visceral obesity) and the terms “metabolic 
syndrome” or “cardiometabolic syndrome” are now more commonly used71. Others again 
look at the SNS as the ‘primum movens’ of these cardiovascular and metabolic alterations59.
A lot of other features and more “non-traditional” risk factors have also been discussed to be 
included in the syndrome like dysfunction of inflammation, coagulation, fibrinolysis, platelets, 
lipoproteins, endothelium, and miscellaneous biological processes. Currently, there are 
different definitions of the metabolic syndrome proposed by international and national 
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organisations or expert group as shown in Table 3. And there is an ongoing discussion about 
the syndrome’s existence. The debate is (in part) related to lack of a universally accepted 
definition, but also due to the aetiology and doubts regarding the need for these disparate 
cardiovascular risk factors to be “lumped” together under one “artificial” diagnostic heading. 
All individual metabolic syndrome components have been shown to be independent risk 
factors for cardiovascular disease and death, so it’s not surprising that the clustering of these 
abnormalities has been reported to be accompanied by a substantial increase in the incidence 
of coronary disease as well as overall cardiovascular morbidity, cardiovascular and all-cause 
mortality59. However, patients known to have this clustering of abnormalities have increased 
cardiovascular risk and an increased risk of developing diabetes mellitus28, 72-75, whether or 
not this is due to the clustering or the individual components themselves.  
Table 3.  Different definitions for metabolic syndrome 
 WHO  
(1999)24
EGIR  
(1999)76
NCEP /ATPIII  
(200177 and *2005 
update78)
IDF
(2005)79
ACE
/AACE80
Main 
criteria 
Insulin resistance or
DM/IGT/ 
IFG6.1mmol/L 
Insulin resistance  3 of the following:  
• Abdominal obesity 
(>102(ƃ)/ 88(Ƃ) cm)* 
• TG1.7 mmol/L 
• HDL<1.0(ƃ)/      
1.3(Ƃ) mmol/L 
• BP130/85 mmHg or
treatment 
• IFG6.1(*5.6)-6.9 
mmol/L or treatment
Central obesity 
(waist 94(ƃ)/
80(Ƃ) cm) 
• TG1.7 mmol/L 
• HDL<1.0(ƃ)/
1.3(Ƃ) mmol/L 
• BP 130/85 mmHg 
• IFG:6.1-6.9 mmol/L 
or IGT 
Other 
criteria 
 2 of the following: 
• BP140/90 mmHg or
treatment
• Dyslipidaemia 
(TG1.7 mmol/L or 
HDL<0.9(ƃ)/       
1.0(Ƃ) mmol/L) 
• Central obesity 
(BMI30 kg/m² or 
waist-hip-ratio 
>0.9(ƃ)/0.85(Ƃ))
• Microalbuminuria 
(AER 20 μg/min or 
albumin:creatinine    
30 mg/g) 
2 of the following: 
• IFG6.1 mmol/L 
• BP140/90 mmHg 
or treatment 
• Dyslipidaemia 
(TG>2.0 mmol/L, 
HDL<1.0 mmol/L or
treatment)
• Central obesity 
(waist90(ƃ)/
80(Ƃ) cm)
2 of the following: 
• BP130/85 mmHg 
or treatment 
• TG1.7 mmol/L or
treatment
• HDL<1.0(ƃ)/ 
<1.3(Ƃ) mmol/L or 
treatment 
• IFG5.6 mmol/L or 
DM2 
Risk factors 
• BMI 
• Non-Caucasian 
• Family DM2, CVD 
• Sedentary lifestyle 
• CVD, PCOS, 
NAFLD, gestational 
DM, acanthosis 
nigrican 
AACE; American Association of Clinical Endocrinologists, ACE; The American College of Endocrinology, 
AER; albumin excretion rate, BMI; body mass index, BP; blood pressure, DM; diabetes mellitus, EGIR; 
European Group for the Study of Insulin Resistance,  IDF; International Diabetes Federation, IFG; 
Impaired fasting glucose, IGT; Impaired glucose tolerance, NAFLD; Nonalcoholic fatty liver disease, NCEP-
ATP III; US National Cholesterol Education Project Adult Treatment Panel, NHLBI; National heart, lung, 
and blood institute, OGTT; oral glucose tolerance test, PCOS; polycystic ovary syndrome, TG; triglycerides, 
WHO; World Health Organization
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4.5 Diabetes development in hypertension 
4.5.1 Pathophysiology 
As part of the metabolic syndrome, hypertension and diabetes mellitus, frequently occur 
together, and both conditions independently increase the propensity to cardiovascular disease 
and organ damage, e.g. greater incidence of stroke, coronary heart disease, congestive heart 
failure, renal failure, peripheral artery disease and cardiovascular mortality81. As discussed 
above insulin resistance may be one pathophysiological mechanism explaining the strong 
relationship69. Endothelial dysfunction and inflammation may be other possible mechanisms 
e.g. markers of inflammation such as C-reactive protein have been consistently related to 
incident type 2 diabetes and to increasing blood pressure levels82-86. Others have linked low 
birth weight with adult hypertension and diabetes mellitus87, 88. The autonomic nervous 
system may also be a possible link89 and will be discussed later. However, as always the 
sequence of events can be discussed and the question is what comes first?90
4.5.2 Consequences 
Diabetes mellitus is a major risk factor for cardiovascular disease including microvascular 
disease and accelerated atherosclerosis with more severe extensive and diffuse lesions 
compared to those in non-diabetic patients49, 54. The risk is added when the patients also have 
hypertension, and the patients with both diabetes mellitus and hypertension have 
approximately four times the cardiovascular risk of non-diabetic non-hypertensive subject49, 50, 
54, 81, 91. The current antihypertensive treatment targets are also lower in diabetic patients 
(<130/80 mmHg) due to higher risk of cardiovascular endpoints3.
The risk associated with new-onset diabetes mellitus or incident diabetes mellitus in 
hypertensives in hypertension trials is not so well characterised. In the up to 16-years follow-
up from the observational PIUMA (Progetto Ipertensione Umbria Monitoraggio 
Ambulatoriale) study, there was a yearly incidence of new-onset diabetes mellitus of 1.9% 
during antihypertensive treatment, and the patients developing diabetes mellitus during 
follow-up developed a risk of a subsequent cardiovascular event that approached those with 
diabetes mellitus at baseline32, 92. Hypertension and incident type 2 diabetes increased the risk 
of coronary heart disease independently, and the combination increased the risk dramatically, 
particularly in women, in a large Finnish population survey50. The coronary heart disease 
incidence was increased by 23% (1.10-1.37) in men and 2.04 times (1.80-2.30) in women 
during 21.5-year of follow-up 50. Results from the MRFIT (Multiple Risk Factor Intervention 
Trial) trial have shown that the patients developing diabetes mellitus during 18-years of 
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follow-up had increased total, cardiovascular and coronary heart disease mortality compared 
to patients without diabetes mellitus93. And among the 282 patients developing new-onset 
diabetes mellitus during 11 years of follow-up in the CHS (Cardiovascular Health Study) 
study, new-onset diabetes mellitus was associated with an increased risk for all-cause and 
cardiovascular mortality compared with non-diabetics with a HR of 1.9 (1.4-2.5) and 2.2 (1.4-
3.4), respectively94. The mortality risk was elevated within 2 years of onset, but surprisingly it 
did not increase further over time94. In a recent published 28-year follow-up study from 
Sweden there was a yearly incidence of new-onset diabetes of 1.0% in hypertensives, and 
there was a greater risk for major cardiovascular complications and mortality in subjects who 
developed new-onset diabetes than in those who did not95. However, this was not seen in the 
same patients at 15 years follow-up96. So the results differ, but most likely the risk of 
developing diabetes is increasing over time. 
In a post-hoc analysis from the ALLHAT (Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial) trial, incident diabetes mellitus was associated with 
a statistically significant increased risk of coronary heart disease with a HR of 1.64 (1.15-
2.32) during the first 2 years of follow-up, but there was no significant increase in any other 
outcomes in association with the diabetes development97. However, the follow-up time was 
short, fasting glucose measurement was only known for half of the cohort, and information 
about possible diabetes treatment was not available97. Similarly, in the extended follow-up of 
the SHEP (Systolic Hypertension in the Elderly Program) study, new-onset diabetes was 
associated with a higher risk of all-cause and cardiovascular mortality in the placebo group, 
but not in the patients treated with diuretic98. However, in these elderly subjects with isolated 
systolic hypertension and high cardiovascular risk in the short term, the highly favourable 
prognostic effect of blood pressure reduction may have outweighed the adverse prognostic 
impact of diabetes development92, 98. The patients from the SHEP report were also not closely 
followed after the randomised part of the trial was stopped and the authors lack information 
about treatment, blood pressure and diabetes development during later follow-up and the 
mortality status was assessed from a national database (National Death Index)98. From the 
Swedish follow-up study discussed above we know it can take even longer than 15 years of 
follow-up to see significant outcome results, and this may also explain why no significant 
differences were seen in the ALLHAT and the SHEP study follow-up99.
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4.5.3 Differences in diabetes development between antihypertensive treatment regimens
All antihypertensive drugs lower (by definition) blood pressure, and this decline is the best 
determinant of cardiovascular risk reduction. However, differences between drugs exist with 
respect of target-organ damage and prevention of cardiovascular events1. Recent guidelines 
recommend five different antihypertensive drugs as first line treatment3. However, there are 
known differences in diabetogenic effect between the regimens56, 100, 101. A net-work meta-
analysis published in Lancet in 2007 have calculated the odds ratio for new-onset diabetes to 
be 0.62 (0.51-0.77) for ARB, 0.67 (0.57-0.79) for ACEI, 0.75 (0.63-0.89) for placebo, 0.79 
(0.67-0.92) for CCB, and 0.93 (0.78-1.11) for beta-blockers compared with treatment with 
diuretics (reference drug=1)56. In the USA 20 million people are treated with thiazide diuretic 
and an equal number are on beta-blockers1. Based on known diabetogenic risk, this translates 
into 250 000 cases of new-onset diabetes mellitus associated with these so-called traditional 
antihypertensive drugs every year1.
Thiazid diuretics may in high-doses worsen glycaemic control by impairing insulin 
secretion and decreasing peripheral insulin sensitivity102. They may worsen glycaemic control 
through stimulation of renin secretion and thereby angiotensin II production. Impaired insulin 
sensitivity has been proposed to be due to increased catecholamine release in response to 
thiazides102. Furthermore thiazide diuretics have a drug- and dose-dependent hypokalaemic 
effect that may blunt the release of insulin from the pancreas103, 104, but potassium 
supplementation and a combination with ACEI or ARB may prevent hypokalaemia.  
There is accumulating evidence that beta-blockers increase the likelihood of new-onset 
diabetes mellitus42, 105, particularly when combined with thiazide diuretics, as shown in the 
ASCOT study106. Potential diabetogenic mechanisms may include weight gain and unopposed 
Į2 receptor-mediated glycogenolysis, inhibition of pancreatic insulin secretion, alteration in 
insulin clearance and, probably most important, reduced peripheral blood flow due to 
increased peripheral vascular resistance107, 108. ȕ1-selective blockers with vasodilating action 
through ȕ2-agonist stimulation or Į-blocking activity appear to have minimal detrimental 
effects on glycaemic control108.
CCBs are considered to be neutral in their effects on glucose homeostasis56, 109.
Vasodilatation and improved peripheral blood flow may explain the improvement in insulin 
sensitivity sometimes seen with calcium channel blockade110. However, in supra-therapeutic 
doses CCB are known to inhibit insulin release111 and some CCBs may activate the SNS112.
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4.6 Renin-angiotensin system (RAS) 
4.6.1 Pathophysiology 
The RAS is a major neurohormonal regulatory system of cardiovascular and renal function to 
maintain haemodynamic stability. It plays an important role in the regulation of blood 
pressure on its own, but it also interacts extensively with other blood pressure control systems 
including the sympathetic nervous system and the baroreceptor reflexes113. RAS is stimulated 
by e.g. blood loss or excessive loss of sodium and water. The classic activation of RAS occurs 
from release of renin by the kidney and renin cleaves angiotensinogen into the inactive 
angiotensin I114. The next rate-limiting step is conversion from angiotensin I into angiotensin 
II by the angiotensin-converting enzyme (ACE) as shown in Figure 1. There are also other 
activation mechanisms and local production of angiotensin II as well as other angiotensin 
peptides, which complicate the picture114, 115. The final step of the RAS cascade is activation 
of angiotensin II receptors, and the clinically important ones are type 1 (and 2)114. The AT1-
receptor belongs to the superfamily of G-protein-coupled receptors and has been localised in 
most tissues including heart, kidney, vascular smooth-muscle cells, brain, adipocytes, platelets, 
adrenal glands and placenta114. The increased level of angiotensin II increases blood pressure 
by stimulation of the AT1-receptor by various mechanisms, including vasoconstriction of 
resistance vessels, aldosterone synthesis and release, renal tubular sodium reabsorption 
(directly and indirectly through aldosterone), thirst stimulation, release of antidiuretic 
hormone and enhanced sympathetic outflow from the brain and noradrenaline release8. In 
addition to promote cardiovascular and renal disease, elevated levels of angiotensin II are 
associated with the development of peripheral insulin resistance116.
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Figure 1. The renin-angiotensin system (RAS) and potential RAS-blockers 
(Modified from Aksnes TA et al. Seminars in Cardiology 2006; 12(4):125-135)  
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4.6.2 Blockers of RAS 
The development of pharmacological agents that block RAS specifically have helped to 
define the contribution of this system to blood pressure control and to the pathogenesis of 
hypertension and renal failure114. Angiotensin II receptor blockade with saralasin in the 1970s 
lowered blood pressure and improved haemodynamics, but had to be administered 
intravenously, and in high doses it had some partial angiotensin-II-like effects114. Later oral 
active ACEI and specific blockers of the angiotensin II AT1-receptor were produced. 
Recently direct oral renin inhibitors have been put on the market117, and other sympatholytic 
agents are also in use (e.g. beta-blockers inhibit renin release from the kidney). RAS-blockers 
have antihypertensive, anti-atherosclerotic, anti-inflammatory, anti-proliferative and oxidative 
stress lowering effects which protect against cardiovascular, cerebrovascular and renal 
damage115.
 So far, seven orally active AT1-receptor blockers or ARBs with different 
pharmacodynamic and pharmacokinetic characteristics are launched in Norway (candesartan, 
eprosartan, irbesartan, losartan, olmesartan-medoksomil, telmisartan, valsartan). ARBs are 
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effective antihypertensive drugs. The blood pressure becomes salt-dependent when RAS is 
blocked, so salt reduction and combination with diuretic increase the antihypertensive 
effect114. ARBs reduce target organ damage like left ventricular hypertrophy, improve 
haemodynamic indices and reduce cardiovascular and end stage renal disease. Another 
important advantage is the tolerability of the drug class as the adverse-effect profile is 
comparable with that seen in placebo groups118.
4.6.3 Effects of RAS blockers on diabetes development and insulin sensitivity  
New-onset diabetes is not a “hard endpoint” like myocardial infarction, stroke and mortality, 
but has been included as an intermediate endpoint in the recent European guidelines3. In the 
network meta-analysis presented above, the relative odds ratio for developing diabetes was 
lowest with long-term use of ARBs 0.62 (0.51-0.77) and next lowest with ACEIs 0.67 (0.57-
0.79) compared with diuretics56. Although a trend, there was no significant difference 
between RAS blockade compared with placebo or between ARBs and ACEIs56.  However, 
these results are predominantly based on data from secondary and post hoc analyses of 
randomised controlled trials, and there are of course also a possible publication bias due to the 
fact that older drugs have been longer on the market and more information are known119. In
the DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) 
trial, treatment with RAS blockade was investigated with new-onset diabetes as a primary end 
point120, and soon results from the ongoing NAVIGATOR (Nateglinide And Valsartan in 
Impaired Glucose Tolerance Outcomes Research)121 and ONTARGET (ONgoing Telmisartan 
Alone and in combination with Ramipril Global Endpoint Trial)/TRANCEND (Telmisartan 
Randomised AssessmeNt Study in ACE- iNtolerant subjects with cardiovascular Disease)122
trials will be published and give further knowledge about RAS-blockade and new-onset 
diabetes. In the DREAM trial treatment with the ACEI ramipril did not reduce the incidence 
of diabetes mellitus or death, but a significant regression towards normal glucose levels was 
observed120. There is today difficult to conclude whether RAS blockade exerts real anti-
diabetogenic action or simply lacks a diabetogenic action possessed by other antihypertensive 
treatment regimens3, but more trials are on their way and will hopefully be able to clarify the 
effect. There are many hypotheses on how RAS-blockade may improve insulin sensitivity and 
reduce diabetes development that will be discussed more extensively later. However, both 
haemodynamic effects with better delivery of insulin and glucose to the peripheral skeletal 
muscle and non-haemodynamic effects including effects on insulin signalling and glucose 
handling, adipocyte differentiation, hypokalaemia and fibrosis prevention, may be of 
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importance100, 123. The ARB telmisartan has even reported to have partial effect on activity of 
the peroxisome proliferator-activated receptor–Ȗ (PPAR-Ȗ), a well-known target for insulin-
sensitising anti-diabetic drugs55. Thus, the effect may involve both improvements of insulin 
secretion as well as insulin action.  
Table 4 shows studies investigating the effect of treatment with ARBs on insulin 
sensitivity measured with hyperinsulinaemic glucose clamp. The reason for differences 
between the study results may be due to different study design and duration, different drugs 
and dosages used, and different patient groups being included in the studies. In spite of some 
mixed results a possible improvement of insulin sensitivity after treatment with ARBs may be 
suspected. 
Table 4. Studies with ARBs investigating insulin sensitivity measured with glucose clamp 
Study Design Drugs Effect ARB 
(p-value) 
Akel et al.124 8 w parallel treatment of 18 hypertensives ARB (losartan) and 
ACEI (enalapril) 
NS 
Aksnes et al. (Paper II) 8 w double-blind crossover study of 17 mild-
moderate hypertensives with other CVD risk factors 
ARB (losartan) vs. CCB 
(amlodipine) 
+17%* 
Fogari et al.125 6 w double-blind crossover study of 25 mild-
moderate hypertensives 
ARB (losartan) vs. ACEI 
(lisinopril) 
NS 
Fogari et al.126† 6 w double-blind crossover study in 28 overweight 
mild-moderate hypertensives
ARB (losartan) vs. ACEI 
(perindopril) 
NS 
Fogari et al.127† 12 w double-blind parallel-group study of 44 
postmenopausal mild-moderate hypertensive women 
ARB (losartan) and 
ACEI (trandopril)  
NS 
Furuhashi et al.128‡ 2 w parallel-group study of 16 insulin-resistant mild-
moderate hypertensives 
ARB (candesartan) and 
ACEI (temocapril) 
+45%*  
Higashiura et al.129‡ 2 w study of 8 mild-moderate hypertensives ARB (candesartan) vs. 
placebo
+42%*  
Iimura et al.130 2 w parallel-group study of 13 mild-moderate 
hypertensives 
ARB (candesartan) and 
ACEI (delapril) 
+42%*  
Laakso et al.131 12 w double-blind parallel-group study of 20 
hyperinsulinaemic hypertensives 
ARB (losartan) and BB 
(metoprolol) 
NS 
Moan et al.132 6 w open-study of severe hypertensives  ARB (losartan) 
vs. placebo 
+30%* 
Moan et al.133 4 w double-blind crossover study of mild 
hypertensives  
ARB (losartan) 
vs. placebo 
NS 
Olsen et al.134 1, 2 and 3 year follow-up of 70 hypertensives with 
ECG-documented LVH (LIFE substudy) 
ARB (losartan) and BB 
(atenolol) 
NS 
Paolisso et al.135 4 w single-blind parallel-group study of 16 insulin-
resistant mild-moderate hypertensives 
ARB (losartan) and 
placebo 
+30%** 
Ura et al.136 2 w parallel-group study of 13 hypertensives ARB (candesartan) and 
ACEI (delapril) 
+42%* 
† and  ‡ ; Partly the same  population, *; p-value<0.05, **; p-value<0.01 
 (BB; beta-blocker, CVD; cardiovascular disease, LVH; left ventricular hypertrophy, NS; non-significant, 
w; week) 
Large hypertension and heart failure trials have reported impact on diabetes 
development in favour of RAS-blockade as shown in Figure 2. CCBs have been considered 
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neutral in case of new-onset diabetes109. However, recently ARBs and ACEIs have shown to 
be associated with significantly less new-onset diabetes than CCBs56, 137, 138. The VALUE 
(The Valsartan Antihypertensive Long-term Use Evaluation) trial was the first opportunity to 
formally compare the effect of an inhibitor of RAS with a CCB on the development of new-
onset diabetes, and the results indicate that the risk for developing diabetes mellitus is either 
lower or delayed in patients treated with valsartan (ARB) than in those treated with 
amlodipine (CCB) with a relative risk reduction of 23% (OR 0.77 (0.69-0.87, p-value< 
0.0001)137. Recently also the CASE-J (The Candesartan Antihypertensive Survival Evaluation 
in Japan Trial) trial has shown a 36% relative risk reduction (HR 0.64 (0.43-0.97), p-
value=0.033) of new-onset diabetes in patients treated with candesartan (ARB) compared 
with amlodipine (CCB)138. There was also a numerical difference in favour of treatment with 
ACEIs compared with CCBs in the results from the ALLHAT trail, however the trial design 
precluded a formal statistical comparison139. In the STOP-2 (Swedish Trial in Old Patients 
with Hypertension-2) study no difference in new-onset diabetes was found140. Although a 
possible favourable effect, it is not establish if RAS blockade reduces or delays the onset of 
type 2 diabetes mellitus.  
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Figure 2. New-onset diabetes mellitus in large trials using blockers of RAS106, 137-139, 141-144
(ACEI; angiotensin-converting enzyme inhibitor, ARB; angiotensin II-receptor     
blocker, BB; beta-blocker, CCB; calcium channel blocker, D; diuretics) 
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4.7 Adipokines 
Since 1994 and the discovery of leptin145,  it has been known that adipose tissue is more than 
a passive storage of fat and energy. Adipose tissue secretes multiple bioactive molecules with 
local or systemic effects called adipocytokines or adipokines. Adiponectin, leptin, and tumor 
necrosis factor-alpha (TNF-Į) are among the best characterised adipokines and have been 
linked with insulin resistance and diabetes development. However, the contribution of the 
various adipokines to the development of insulin resistance is complex and not fully 
understood. It has also been hypothesised that blockade of RAS promotes the recruitment and 
differentiation of pre-adipocytes into small insulin-sensitive adipocytes that counteract ectopic 
deposition of lipids and thereby improves insulin sensitivity146.
Low plasma levels of the adipokine adiponectin has been associated with obesity and 
type 2 diabetes mellitus in different ethnic groups, and it has been shown that circulating 
adiponectin levels correlate better with insulin resistance and hyperinsulinaemia than 
adiposity and glucose intolerance147-151. Adiponectin increases rates of fatty acid oxidation 
and decreases muscle lipid content which may in part be the underlying mechanism to their 
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possible insulin sensitising effect57. More recently, it has been hypothesised that low 
adiponectin might be involved in development of hypertension152, 153. In Table 5 studies 
investigating and reporting effects of treatment with ARBs on insulin sensitivity and 
adiponectin levels are shown, and although some mixed results a trend towards improvement 
of both insulin sensitivity and adiponectin after ARB treatment may be sensed128, 154-165. There 
are different hypotheses of how RAS-blockade may increase adiponectin levels e.g. RAS-
blockade may promote and increase adipogensis and adipocyte differentiation that may result 
in a greater capacity for adiponecetin production146. It has also been shown that RAS blockade 
may suppress TNF-Į synthesis166, which again suppresses adiponectin expression167-169. The 
effects may also be on gene expression as at least one ARB, telmisartan, has shown to act as a 
PPAR- Ȗ agonist like the thiazolidinediones55, 167, 170. One experimental study has concluded 
that ARB-induced adiponectin stimulation is most likely to be mediated via PPAR-Ȗ
activation involving a post-transcriptional mechanism171, but this does not explain the positive 
effect seen of other RAS-blockers with less known PPAR-Ȗ effect172. Animal models have 
also indicated that blockade of angiotensin II-receptor ameliorates adipokine dys-regulation in 
obese, and that such action is mediated by preventing oxidative stress in obese adipose 
tissue173. In addition to adiponectin’s strong association with type 2 diabetes mellitus, a 
possible association between high adiponectin concentrations and a favourable cardiovascular 
risk profile has been suggested174. However, this association with coronary heart disease is 
more moderate and requires further investigation174.
Leptin is polypeptide derived from adipose tissue that promotes weight loss by acting 
in the hypothalamus to reduce appetite175. Results from studies of individuals with leptin 
deficiency176 or leptin receptor defects177, have revealed a critical role of leptin in the normal 
regulation of appetite and adiposity in humans. The primary biological role of leptin appears 
to be adaptation to low energy intake rather than to inhibit over-consumption and obesity170.
Leptin is considered to play a key role in the elevation of sympathetic activity commonly 
found in obese hypertensive patients178, 179, presumably by means of increasing caloric 
expenditure and losing weight59. It exerts a direct effect on the kidneys resulting in increased 
sodium reabsorption and regulates vasomotion180. Leptin may decrease muscle lipid content 
which may in part improve insulin sensitivity57. Leptin has also shown pro-atherosclerotic, 
pro-inflammatory, and pro-thrombotic effects. 
The adipokine resistin was discovered in 2001 by screening for genes that were 
induced during adipocyte differentiation and down-regulated in mature adipocytes treated 
with thiazolidinediones, and it got its name due to the thinking of this being the linkage 
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between obesity and diabetes (RESISTance to INsulin)181. In mice studies high levels of 
resistin have shown to correlate with insulin-resistant states, and resistin administration has 
led to insulin resistance in vivo and in vitro studies59. However, there are differences in 
protein structure between mice resistin and human resistin, and the link between obesity and 
diabetes in humans has shown to be complicated. Resistin has been shown to directly impair 
insulin signalling and insulin stimulated glucose uptake in muscle, but has not shown direct 
effect on altering muscle lipid metabolism.
Plasminogen activator inhibitor type 1 (PAI-1), an inhibitor of fibrinolysis, is another 
protein related to adipocytes. It has been linked to a variety of biological processes and is 
secreted by adipocytes, hepatocytes, platelets and vascular smooth muscle and endothelium182, 
183. Elevated level of PAI-1 may predict future diabetes mellitus and cardiovascular disease in 
part because elevated levels also reflect visceral obesity and insulin resistance82, 182, 183.
Weight loss and improvement in insulin sensitivity due to treatment with anti-diabetic drugs 
have shown significant reduction in circulating PAI-1 levels183. In the Framingham Study, 
PAI-1 had a positive graded relationship with development of type 2 diabetes mellitus, and 
the association was independent of other risk factors including obesity, homeostasis model 
assessment for insulin resistance (HOMA-IR), IFG/IGT, triglycerides and inflammation82.
TNF-Į is a pro-inflammatory cytokine and has been suggested to play a key role in 
insulin resistance in obesity and may contribute to the development of type 2 diabetes 
mellitus184. One possible mechanism may be by impaired insulin signalling and tyrosine 
kinase activity at the insulin receptor, which is important for the biological activities of 
insulin185. Other mechanisms may be that TNF-Į increase release of free fatty acids from 
adipocytes and reduce adiponectin synthesis168. At least one study has shown reduction of 
TNF-Į with ARB treatment186, and effects through modulation of RAS may be another 
linkage between TNF-Į and insulin resistance. 
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Table 5. Studies with ARBs reporting effect on insulin sensitivity and adiponectin 
Study Design 
Insulin  
sensitivity Adiponectin 
Aksnes et al.(Paper III)  21 HT, losartan 8w + +/- 
Benndorf et al.154 37 HT, telmisartan 6w + +/- 
Chujo et al.155 28 HT, telmisartan 24w +/- (+†) + 
de Vinuesa et al.156 52 CKD, olmesartan 16w + +/- 
Furuhashi et al.128 16 HT, temocapril/ candesartan 14 d  + + 
Koh et al.157 47 HT with hypercholesterolemia, losartan 2m + + 
Koh et al.158 45 HT, candesartan 2m  + + 
Koh et al.159 44 HT with hypertriglyceridaemia, candesartan 2m + + 
Negro et al.160 46 HT with IR, irbesartan or telmisartan 6m + + 
Nielsen et al.161 9 men with DM1, losartan 6w + + 
Park et al.162 44 HT with IR and DM, losartan 6m + + 
Usui et al.163 36 HT with DM2, telmisartan 6m + ‡ +/- 
Yenicesu et al.164 21 DM2 with proteinuria, ramipril 4w + + 
Yilmaz et al.165  20 HT with MetS, valsartan 3m + + 
* CKD; chronic kidney disease, d; days, DM; diabetes mellitus, HT; hypertensives, IR; insulin-resistant, m; 
months, MetS; metabolic syndrome, w; weeks, +; positive effect, +/-; neutral effect (non-modified effect) 
† In patients with MetS (n=14). ‡ In patients not taking anti-diabetic drugs (n=14). 
4.8 The autonomic nervous system 
The nervous system is divided into the somatic nervous system that controls organs under 
voluntary control (mainly muscles) and the autonomic nervous system (or visceral nervous 
system) that regulates individual organ function and homeostasis, and for the most part is not 
subject to voluntary control e.g. regulation of heart rate, respiration and digestion. The 
autonomic nervous system commands the organs through two antagonistic branches: the 
sympathetic nervous system, predominant in the active period (“fight, fright, and flight”), 
whereas the parasympathetic nervous system rules the body in the inactive period (“rest and 
digest”). 
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4.8.1 The sympathetic nervous system 
The sympathetic nervous system is the portion of the autonomic nervous system that enables 
the body to be prepared for fight or flight. Sympathetic responses include increase in heart 
rate, blood pressure, and cardiac output and diversion of blood flow away from the skin and 
splanchnic vessels to the blood vessels supplying skeletal muscle187. Efferent sympathetic 
activity releases noradrenalin and adrenalin from sympathetic nerve endings and from the 
adrenal medulla, and the cells containing adrenaline and noradrenaline are innervated by 
separate sympathetic neurons and descending pathways from the hypothalamus188.
Noradrenaline is the main postganglionic transmitter of the sympathetic nervous system in 
regulation of the cardiovascular system and sympathetic neural activity evokes and decays 
slower than the corresponding response to stimulation of the parasympathetic nervous system 
or vagal activity189. This is due to slow noradrenaline release, the slow 2nd messenger system 
coupling the adrenergic ȕ-receptors and the ion channels, and the slow removal of 
noradrenaline by cellular re-uptake and urinary excretion190. Increased activity of the 
sympathetic nervous system is thought to play an important role in the pathogenesis and 
maintenance of essential hypertension, especially in the early phase of hypertension8, 191, 192.
The specific cause of the increased sympathetic activity in essential hypertension remains 
largely unknown, although genetic influences are evident and behaviour and lifestyle factors 
like stress, physical inactivity and obesity are involved192. Noradrenaline released from 
sympathetic nerve endings in the kidney, heart, and blood vessels raises blood pressure by 
enhancing sodium reabsorption, increasing cardiac output, and increasing peripheral 
resistance193. According to the hypothesis of Julius68 enhanced sympathetic activity is the 
primary factor that can be associated with both hypertension and insulin resistance, and 
possibly obesity. The pressure-induced restriction of the microcirculation limits nutritional 
flow and thereby impairs glucose uptake in the skeletal muscle89, which is the major site of 
insulin resistance194. On the other side Landsberg193 has proposed hyperinsulinaemia as the 
primary cause of hypertension partly through increased sympathetic activity, and this classic 
“chicken and egg”-question is still not solved. The adverse effects of sympathetic activation 
in hypertension are both promotion of atherosclerosis and unfavourable effect on the 
metabolic profile by development and progression of insulin resistance and dys-lipidaemia195.
Locally released noradrenaline from sympathetic nerves is likely to increase glucose 
uptake in skeletal muscle and adipose tissues through ȕ-adrenergic stimulation and through 
insulin-independent mechanisms196. However, noradrenaline does not contribute so much as 
adrenaline to hepatic glucose production, and in the long term sympathetic activation may 
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reduce skeletal muscle glucose uptake through microvascular changes196, 197. Chronic 
sympathetic over-activity may produce insulin resistance by receptor mechanisms, decreased 
capillary density, or by Į-receptor-mediated vasoconstriction89, 198.
Sympathetic activation also increases adipose tissue lipolysis and releases free fatty 
acids into circulation and thereby producing another mechanism that directly inhibits glucose 
transport across the cell membrane59. There is a direct relationship between the number of 
sympathetic neural bursts to skeletal muscle tissue and insulin sensitivity assessed by HOMA-
IR199, indicating a linkage between insulin resistance and  increased sympathetic activity. The 
number of sympathetic bursts to skeletal muscle circulation is also greater in diabetic patients 
as well as in individuals with diabetic parents that still have normal blood glucose59, 200.
RAS and SNS are linked by a positive feedback relationship9. The stimulating effect 
of sympathetic nerves on renin release from juxtaglomerular cells in the kidney is 
reciprocated by the sympathostimulation caused by angiotensin II through a variety of 
peripheral (increase in noradrenaline release from sympathetic nerve terminals, potentiation of 
the adrenoceptor responsiveness to adrenergic stimuli) and more central (brain and ganglionic 
influences of angiotensin II) mechanisms59. Angiotensin II has shown inhibitory effects on 
baroreceptor reflex control of heart rate9, 113. It facilitates sympathetic and suppresses 
parasympathetic activity, and RAS blockers may restore the autonomic balance201, 202.
Dihydropyridine CCBs exert their blood pressure reducing effect through a decrease in 
peripheral resistance due to arterial vasodilatation and have showed mixed results in relation 
to SNS203. In a study comparing different dihydropyridine CCBs, a significant increase in 
plasma noradrenaline levels were observed after chronic therapy with amlodipine and 
felodipine, but not with the lacidipine and manidipine204. Sympathoinhibition cannot be 
obtained by CCBs whose administration may be accompanied by an increase, or at best, no 
change in sympathetic activity195. The possible increase of sympathetic activity by some 
CCBs, especially triggered by the acute blood pressure reduction, may make them fail to 
improve metabolic function195.
Other antihypertensive treatment regimens like diuretics may increase central 
sympathetic nervous system activity, and alfa-1 adrenergic antagonists may induce a 
reflectory increase in plasma noradrenaline due to peripheral arterial pressure reduction205. As 
expected beta-blockers and central sympatholytic antihypertensive drugs may reduce SNS 
activity205.
SNS in humans may be assessed by heart rate and haemodynamic measurements, 
noradrenaline measurement in urine and plasma, neurotransmitter release by radiotracer-
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derived measurements, microneurographic recordings, heart rate variability (HRV), baroreflex 
sensitivity (BRS), positron emission tomography (PET) and other imaging techniques59, 206.
4.8.2 The parasympathetic nervous system 
This part of the autonomic nervous system has opposite effects of the sympathetic nervous 
system and causes a reduction in heart rate and blood pressure, facilitates the digestion and 
absorption of nutrients, and excretion of waste products from the body187. The
parasympathetic nervous system regulates cardiovascular function through the action of 
acetylcholine on muscarinic cholinergic receptors. Stimulation of the parasympathetic 
nervous system by the vagus nerve reduces heart rate, inhibits atrioventricular conduction and 
reduces myocardial contractility. Due to fast coupling of muscarinic receptors to potassium 
channels and quick hydrolysis of acetylcholine by acetylcholinesterase, the parasympathetic 
nervous system allows for beat-by-beat control of heart rate190.
 Parasympathetic cardiovascular control tends to be reduced in patients with essential 
hypertension. However, this has received much less attention than activation of the 
sympathetic nervous system, probably due to methodological reasons and due to no direct 
“parasympathetic” antihypertensive drug207. Increased sympathetic activity and decreased 
parasympathetic activity have been linked not only to hypertension, but also to the associated 
metabolic abnormalities198, 208.   
Cardiovascular parasympathetic nervous system activity may be studied indirectly 
through haemodynamic measurements during pharmacologic blockade or assessment of BRS 
and HRV analyses207, 209.
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5.  Aims of the thesis 
The aims of the thesis were to investigate insulin resistance and development of diabetes 
mellitus in hypertensives. The main specific questions addressed can be summarised as 
follows: 
1. Patients with hypertension and high cardiovascular risk may also have a high risk of 
developing diabetes mellitus. What predicts diabetes development among 15245 high 
risk hypertensive patients? (Paper I) 
2. May additional antihypertensive treatment with AT-1 receptor blockade improve 
insulin sensitivity measured with the hyperinsulinaemic isoglycaemic glucose clamp 
compared to treatment with calcium channel blocker alone? (Paper II) 
3. We aimed to investigate the influence of AT-1 receptor blockade on circulating 
adipokines, inflammatory markers and blood viscosity (Paper III) 
4. We aimed to investigate if different effects on the sympathetic-parasympathetic 
balance measured with BRS, HRV and plasma catecholamines may be related to the 
changes in glucose metabolism after treatment with additional AT-1 receptor blockade 
compared to calcium channel blocker alone? (Paper IV) 
5. May development of diabetes mellitus in hypertensives during antihypertensive 
treatment affect cardiac outcomes? (Paper V)     
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6.  Material and methods 
6.1 The GOAAL study 
6.1.1 Study design and subjects 
The Glucose Optimisation with the Angiotensin II Antagonist Losartan in patients with 
hypertension and other cardiovascular risk factors (GOAAL) study is a double-blind, 
randomised crossover study designed to compare the metabolic effects of 10 mg amlodipine 
and 100 mg losartan + 5 mg amlodipine. After a 4-week open label amlodipine 5 mg run-in 
period, all hypertensive patients were randomised to additional treatment with either 
amlodipine 5 mg or losartan 100 mg for 8 weeks (Fig.3). At the end of this 8-week treatment-
period, patients underwent blood pressure measurement, blood sampling, a hyperinsulinaemic 
isoglycaemic glucose clamp and BRS/HRV measurements. Following this was a 4-week 
wash-out phase where the patients continued open label 5 mg amlodipine, and then they were 
crossed over to the opposite treatment regimen for another 8 weeks before the final 
examination with blood pressure measurement, blood sampling, hyperinsulinaemic 
isoglycaemic glucose clamp and BRS/HRV measurements  
The study was approved by the National Committees for Research Ethics in Norway 
and the Norwegian Medicines Agency. All patients gave verbal and written informed consent 
to participate before included in the study.  
36
Figure 3. Study design  
(Modified after Figure 2 in Paper II) 
Consent                Glucose clamp                          Glucose clamp
History & PE           Safety labs Safety Labs Safety labs               Safety labs
I/E criteria               BP                       BP                                    BP                 BP
Safety labs                        BRS/HRV          BRS/HRV
24-h ECG              24-h ECG
”Run-in”
4 weeks
Losartan 100 mg 
V1 V2 V3 V4 V5
8 weeks
”Wash-out”
4 weeks
”Open label” Amlodipine  5 mg
Amlodpine 5 mg 
Losartan 100 mg
8 weeks
Amlodipine 5 mg 
BP; blood pressure, BRS; baroreflex sensitivity, Glucose clamp; hyperinsulinaemic isoglycaemic glucose 
clamp, HRV; Heart rate variability, I/E; inclusion/exclusion, labs; laboratory tests, PE; physical examination, 
V1, V2 etc; visit 1, visit 2 etc, 24-h ECG; 24-hour electrocardiography recording
Twenty-five patients with mild to moderate essential hypertension (office diastolic 
blood pressure 95-110 mmHg and systolic blood pressure <180 mmHg) were recruited from 
general practitioners in the city of Oslo. The participants were previously untreated (n = 4) for 
hypertension or treated with monotherapy (n = 21), but not with ACEIs or ARBs. All patients 
had to have IGT or IFG defined as fasting plasma glucose of 6.1-7.0 mmol/L. The participants 
also had to have either microalbuminuria (urine albumin excretion rate 20μg/min), dys-
lipidaemia (HDL-cholesterol <0.9 mmol/L or triglycerides >1.7 mmol/L), BMI >28 kg/m² or 
an increased waist-to-hip ratio (>0.9 for men and >0.85 for women) according to some of the 
WHO criteria for metabolic syndrome24. At the first visit a clinical examination and 
laboratory testing with electrolytes, creatinine and thyroid hormones were taken to screen for 
secondary hypertension. 
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Due to side effects of the study medication (ankle oedema, headaches, flushing and 
palpitation), three patients decided to withdraw during the study and are not included in the 
final analysis. One of the patients who completed the study was excluded from the analyses 
due to an error at the hospital pharmacy (the patient was given amlodipine 10 mg throughout). 
Thus, the final study population consisted of 21 subjects (Fig. 4); 11 women and 10 men. The 
mean age was 58.6 years (range 46-75 years). At inclusion, blood pressure averaged 160 ± 
3/96 ± 2 mmHg and heart rate 66 ± 2 beats/min. BMI was 29.2 ± 1.0 kg/m² in the whole study 
group and the waist-to-hip ratio was 0.92 ± 0.01 in the women and 1.05 ± 0.01 in the men. 
Four patients (19%) were previously untreated for their hypertension and seven (33%) were 
previously treated with thiazides, four (19%) with beta-blockers and six (29%) with a CCB. 
Five (24%) subjects were smokers. Four of the patients did not complete two glucose clamps 
due to technical problems during the clamp procedure.   
Figure 4. Study population 
(Modified after Figure 1 in Paper II) 
3 patients withdraw due 
to side effects of the 
study medication
1 patient excluded due to error in 
study medication by the local 
pharmacy
STUDY POPULATION:
21 patients
4 patients without two satisfactory 
hyperinsulinaemic isoglycaemic 
glucose clamp examinations
17 patients 
completed two hyperinsulinaemic 
glucose clamp examinations
25 patients 
included
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6.1.2 Study endpoints 
6.1.2.1 Hyperinsulinaemic isoglycaemic glucose clamp and measurement of insulin sensitivity 
A number of methods have been developed for the quantitative measurement of insulin 
sensitivity, but the hyperinsulinaemic glucose clamp is still considered the “gold standard”60.
The hyperinsulinaemic isoglycaemic glucose clamp in our study was performed after an 
overnight fast. Antecubital veins on the right and left arm were cannulated with short Teflon 
catheters (Optiva® 2, 18G; Medex Medical Ltd., Haslingden, Great Britain) and glucose and 
insulin were infused through one catheter, whereas the other catheter was used for blood 
sampling. The hyperinsulinaemic isoglycaemic glucose clamp was performed for 120 minutes 
using a modification of the method described by DeFronzo et al.60. The insulin infusion was 
prepared in a bag with 100 ml of 0.9% saline. To prevent insulin from adhering to the plastics, 
4 ml of saline was exchanged with 4 ml of whole blood from the patient, and 30 IE of Insulin 
Actrapid were then added to the saline + whole blood mixture and shaken well. The mixture 
was then drawn into a 50 ml syringe and infused at a fixed rate of 0.001 IE/ kg body weight/ 
min. The fasting blood glucose level was determined as the average of 3 measurements with 
an Accu-Chek® Sensor (Roche Diagnostics GmbH, Mannheim, Germany). The insulin 
infusion was kept unchanged during the clamp, and the glucose infusion (200 mg/ml) was 
started after 5 minutes at a rate of 20 ml/hour and was adjusted every 5 minutes according to 
the blood glucose level to keep the blood glucose concentration isoglycaemic or at the 
baseline level. Insulin sensitivity was expressed as the glucose disposal rate (GDR) 
(mg/kg/min), calculated from the average glucose infusion rate during the last 20 minutes of 
the 120 minute clamp. This technique for measuring insulin sensitivity has a coefficient of 
variation of less than 5% in our laboratory210. However, the glucose clamp technique is time-
consuming and expensive so more easily accessible methods have also been developed. 
Fasting insulin per se is a much easier way of measuring insulin sensitivity. However, 
in patients with pre-diabetes or diabetes the hyperglycaemia is accompanied by inadequate 
insulin secretion, and the relationship with insulin sensitivity is not so reliable. Therefore 
different indexes have been developed. The HOMA-IR is calculated in fasting conditions as 
serum glucose (mmol/L) multiplied by serum insulin (pmol/l) and divided with 135, as 
described by Matthews et al.211. HOMA-IR has shown to correlate well with euglycaemic 
clamp measures in men and women, young and older adults, and obese and non-obese 
individuals211, 212. HOMA and other indexes are proxies for these more complex measures like 
the glucose clamp as they do not provide the same depth of physiological information74.
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6.1.2.2 Blood pressure and heart rate 
Blood pressure was measured with a mercury sphygmomanometer with adequate cuff size 
and after 5 minutes rest in sitting position. The pressure was measured at least three times and 
the values registered were the mean of the two latest measurements. Resting heart rate was 
measured by pulse palpation for 30 seconds after the blood pressure measurement. 
6.1.2.3 Heart rate variability (HRV) 
HRV is the oscillation in the interval between consecutive heart beats as well as the 
oscillations between consecutive instantaneous heart rates209. The clinical relevance has been 
appreciated for more than forty years209, 213, however, the linkage between reduced variability 
and cardiac mortality has first been known later209, 214. HRV can be measured using time 
domain and frequency domain analysis of electrocardiographic (ECG) recordings and has 
emerged as one important non-invasive methods to measure tonic autonomic heart rate 
control209, 215.
Time domain variables are calculated from the R-R intervals or normal-to-normal 
(NN) intervals that is the intervals between two successive normal QRS complexes in the 
ECG. Thus, the mean R-R interval reflects heart rate, whereas the variable SDNN (standard 
deviation of the NN interval) is the square root of variance and reflects all cyclic components 
responsible for variability in the period of recording209. Other time domain variables measure 
high-frequency variations in heart rate, and these include the square root of the mean squared 
differences of successive NN (RMSSD) and the proportion of interval differences of 
successive NN intervals greater than 50 ms (PNN50). As the total variance of HRV increases 
with the length of the recording, the durations used should be standardised e.g. with short-
term 5-min recordings and 24-h long-term recordings as suggested by the Task Force of The 
European Society of Cardiology and The North American Society of Pacing and 
Electrophysiology209.
Frequency domain variables, derived from power spectral analysis of R-R interval 
variability, estimate the distribution of power (or variance) as a function of frequency209. The 
power components are very low frequency (VLF; 0.04 Hz), low frequency (LF; 0.04-0.15 
Hz) and high frequency (HF; 0.15-0.4 Hz) and measurements are usually made in absolute 
values of power (ms²), but normalised units (n.u.) of LF and HF may also be measured and 
represent the relative value of each power component in proportion to the total power minus 
the VLF component209.  The normalisation minimises the effect of change in total power and 
represents the balance of the two branches of the autonomic nervous system209. The HF 
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component reflects efferent vagal or parasympathetic activity, and on the contrary the LF 
component is thought to reflect both sympathetic and parasympathetic influences209. Low 
HRV and LF have been related to development of hypertension216, as well as insulin 
resistance and diabetes mellitus217, 218. Both short-term recordings (5 minutes) and long-term 
recordings (24-hour) may be used in the analyses 209.
We measured HRV using a finger blood pressure monitor (Finometer®, Finapres 
Medical System, Amsterdam, The Netherlands) and a Mingograph 7 recorder (Siemens Elema, 
Solna, Sweden) for 40 minutes during supine rest prior to the clamp procedure. HRV was 
computed using BeatScope (BeatScope® Finapres Medical System, Amsterdam, The 
Netherlands) and Nevrokard (Nevrokard® Medistar, Ljubljana, Slovenia) software program 
for short-term recordings of 5 minutes for frequency domain methods. The 5 minutes 
recordings were checked, and the intervals free of missing data and with a minimum of 
ectopic beats and noise were chosen as recommended209. Normalised HF and LF, and LF/HF 
ratio were analysed. 24-hour Holter recordings were analysed with HRV time domain 
methods using Novacor Holter software (Novacor HolterSoft Ultima version 2.3.1, Cedex, 
France). The mean R-R interval, SDNN, and PNN50 were measured. The same person did all 
the visual checks and manual corrections of individual RR intervals and QRS complex 
classification. 
6.1.2.4 Baroreflex sensitivity (BRS) 
In the clinical setting BRS can be assessed by studying either the reflex heart rate response to 
physiologic activation or deactivation of the baroreceptors obtained by a variety of 
mechanical or pharmacologic manipulations, or by analysing the spontaneous fluctuations of 
the arterial pressure in steady-state conditions measured as the ratio between changes in RR 
interval time and changes in systolic blood pressure (msec/mmHg)219. The development of a 
device for non-invasive measurement of arterial pressure (FINger Arterial PRESsure) has 
made measurements of BRS more easy accessible219, 220. Non-invasively measured 
“spontaneous BRS” correlates well with results obtained by the pharmacological techniques, 
and one important advantage is that no external intervention (except cuff application) is 
required221, 222.  The cuff pressure oscillations have been found to resemble the intra-arterial 
pressure wave in most subjects, and changes of blood pressure can be accurately estimated, 
although the absolute values may be underestimated (or overestimated) in some subjects220.
BRS measures the dynamic autonomic heart rate control, and cardiac baroreflex response to 
increase blood pressure is mediated by the parasympathetic nervous system215, 219. BRS 
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increases when there is a shift of the autonomic balance towards an increased parasympathetic 
dominance219. Both BRS and HRV are reduced in high normal blood pressure and 
hypertensive patients, and even more in hypertensives with hyperinsulinaemia223-225.
We measured BRS based on the beat-to-beat blood pressure and heart rate recordings 
performed with the Finometer and the Mingograph 7 as for the HRV analyses, and 5 minutes 
segments were used for BRS analyses using the Nevrokard software program.
6.1.2.5 Catecholamines 
Sympathetic activity can be estimated by measurement of the plasma concentration or urinary 
excretion of catecholamines and their precursors and metabolites226. Measurement of plasma 
noradrenaline concentration in venous blood represents the most commonly employed index 
of sympathetic activity in man226. Plasma catecholamine concentrations at our laboratory are 
measured with a validated radioenzymatic technique227, 228. Arterial catecholamines may be 
better than venous catecholamines when comparing hypertensive and normotensive groups228,
as arterial samples reflect the sympathetic tone from heart and kidney better than venous due 
to  skeletal muscle contributes to approximately 50% of peripheral venous noradrenaline229.
However, due to ethical considerations and discomfort to the patients, we used venous 
catecholamine. Measurement of plasma noradrenaline represents only a small fraction of the 
total noradrenaline released from sympathetic nerves and is also dependent on tissue 
clearance and neuronal re-uptake and does not discriminate between the central or peripheral 
nature of increased plasma noradrenaline and the regional differentiations226. Other 
measurements of increased sympathetic activity e.g. microneurographic analysis have been 
considered more optimal226, but were not used in our study.  
Most of the circulating adrenaline is derived from the adrenal medulla189, and an 
increase in plasma adrenaline is generally considered to indicate increased adrenaline 
secretion, although changes in clearance may also modify the concentration189.
6.1.2.6 Whole blood viscosity (WBV) 
Whole blood is a non-Newtonian solid-liquid suspension and whole blood viscosity (WBV) 
depends on the concentration of cellular elements and the viscosity of plasma. With a 
rotational rheometer, fluidity of blood can be measured over a range of shear stresses (or 
shear rates). The liquid is sheared between two surfaces under constant shear stress or shear 
rate and the resulting shear rate is measured as a response to the applied movement. We 
measured WBV with a controlled stress rotational rheometer (CS10, Bohlin Instruments Ltd, 
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Lund, Sweden), with a double gap measuring system. The rheological properties of blood in 
patients with essential hypertension are known to be altered compared to healthy subjects, and 
WBV is directly correlated to the blood pressure levels230. Previous studies from our group 
have shown that WBV is negatively related to insulin sensitivity210, 231.
6.1.2.7 Other laboratory analyses 
C reactive protein (CRP) got its name due to capacity to bind to the c-polysaccharide of 
streptococcus pneumoniae and is a known biomarker of cardiovascular disease, and a 
relationship between CRP and insulin resistance has been shown232. The values of high 
sensitivity CRP (hs-CRP) of < 1, 1-3, and > 3 mg/L correspond with low, moderate, and high 
cardiovascular risk across a wide group of patient233. Measurement of hs-CRP should ideally 
be performed in a metabolically stable person without obvious inflammatory or infectious 
conditions and be repeated within two weeks233, however this was not possible in our study 
due to the study design.  
6.2 The VALUE trial 
6.2.1 Study design and subjects 
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial is an investigator-
designed, prospective, multi-centre, double-blinded, randomised, active-controlled, parallel-
group trial. The primary objective was, for the same level of achieved blood pressure, to 
compare the long-term effects on the incidence of cardiac morbidity and mortality between 
antihypertensive treatment with the ARB valsartan and the CCB amlodipine. The trial was 
endpoint driven and the patients were followed for 4-6 years with regular visits, and upward-
titration of medication was implemented in five steps to reach a goal blood pressure below 
140/90 mmHg. The trial included 15245 patients older than 50 years who were treated (92%) 
or untreated for essential hypertension at baseline234. Previously untreated patients were 
included if they had a mean sitting systolic blood pressure between 160 and 210 mmHg 
(inclusive) and a mean sitting diastolic blood pressure below 115 mmHg, or a mean sitting 
diastolic blood pressure between 95 and 115 mmHg (inclusive) and a mean sitting systolic 
blood pressure below 210 mmHg235. For patients already on antihypertensive treatment the 
mean sitting blood pressure should not exceed 210 mmHg systolic and 115 mmHg diastolic, 
but there was no lower limit. Additional inclusion criteria were the presence of predefined 
combinations of cardiovascular risk factors and/or disease factors according to an algorithm 
based on age and gender235. The qualifying risk factors included diabetes mellitus, cigarette 
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smoking, hypercholesterolemia, proteinuria, serum creatinine >150 Pmol/l and left ventricular 
hypertrophy (LVH) without strain on ECG using Cornell236 or Sokolow-Lyon criteria237.  The 
qualifying disease factors included documented history of myocardial infarction or significant 
coronary heart disease (e.g. documented on arteriogram), peripheral vascular disease, cerebral 
stroke or transient ischemic attack, or the presence of LVH with strain on ECG. Women aged 
50-59 years had to have at least one disease factor and two risk factors, while men in the same 
age-group only had to have one disease factor or three risk factors to enter into the trial. For 
men and women 60-69 years at least two risk factors or one disease factor were required, and 
for patients above the age of 70 years only one risk factor or one disease factor were required 
for randomisation.  
6.2.2 Study endpoints 
6.2.2.1 New-onset diabetes mellitus 
We wanted to investigate patients patients that developed diabetes mellitus during the 
VALUE trial. All patients who at entry were diagnosed as diabetics, received anti-diabetic 
agents, or had abnormal glucose levels were excluded in the analysis of new-onset diabetes 
mellitus. To detect new-onset diabetes mellitus in the VALUE trial three different criteria 
were used, but patients could only be counted once. The criteria were:
1. Diabetes mellitus reported by the investigators as an adverse event during the trial. 
(The investigators were strongly encouraged to use the WHO 1999 criteria24)
2. Information about new use of oral anti-diabetic drug or insulin in study reports. This 
database contained a detailed directory of drugs by both generic and trade names in all 
participating countries. 
3. Fasting glucose concentration >7.0 mmol/L in a venous blood sample drawn at study 
end and analysed in a central laboratory. 
Diabetes mellitus was at baseline234 defined by the WHO 1985 criteria (fasting glucose 7.8
mmol/L on at least two separate occasions)238. In 1999, during the course of the study, WHO 
changed the definition of diabetes mellitus to a fasting blood glucose of >7.0 mmol/L and/or 
blood glucose >11.1 mmol/L two hours after oral intake of 75 g glucose24. During the blinded 
phase of the trial, the working classification of new-onset diabetes mellitus was therefore 
redefined to adhere with the WHO 1999 criteria24, and this protocol was pre-specified in a 
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study newsletter. Consequently new-onset diabetes mellitus in our manuscripts is defined as 
fasting blood glucose of >7.0 mmol/L during the trial in patients without diabetes mellitus or 
with blood glucose <7.0 mmol/L at entry. The new definition increased the number of 
diabetics at entry of the VALUE trial by 427, and these patients are also excluded from the 
analysis of new-onset diabetes mellitus. 
According to these criteria, we have divided the 15245 patients in the VALUE trial 
into three pre-specified groups; patients with diabetes at baseline, patients that developed 
diabetes during the average 4.2 years of the trial and patients without diabetes both at baseline 
and at the end of the trial. 5250 patients were diabetic at baseline, and 1298 of the initial 9995 
non-diabetic patients developed diabetes mellitus during the average 4.2 years of the VALUE 
trial. 
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7. Summary of results 
7.1 Paper I 
The risk of developing diabetes mellitus among the non-diabetic VALUE trial population of 
hypertensive patients with high risk of cardiovascular disease was investigated. Easily 
accessible baseline clinical characteristics (glucose, BMI, non-Caucasian race, low age, heart 
rate and history of coronary heart disease (CHD)) predict patients at risk of developing 
diabetes mellitus. Baseline blood glucose and BMI were by far the most important baseline 
predictors of new-onset diabetes mellitus in the VALUE trial population. 
7.2 Paper II 
Additional treatment with ARB improved insulin sensitivity (GDR) measured with 
hyperinsulinaemic isoglycaemic glucose clamp, compared with treatment with CCB alone 
despite similar blood pressure reduction. The GDR was significantly higher after treatment 
with losartan 100 mg + amlodipine 5 mg compared to amlodipine 10 mg (4.9 ± 0.4 vs.        
4.2 ± 0.5 mg/kg/min, p-value=0.039) in hypertensives with other cardiovascular risk factors. 
Thus our data suggest that AT-1 receptor blockade with losartan improves glucose 
metabolism beneficially through mechanisms at the cellular level, beyond what can be 
expected by the vascular vasodilating effects and blood pressure reduction alone. 
7.3 Paper III 
No significant differences in adipokines, viscosity, inflammatory and fibrinolytic markers 
were found after treatment with losartan 100 mg + amlodipine 5 mg compared to treatment 
with amlodipine 10 mg. The difference in insulin sensitivity previously found after additional 
treatment with ARB compared with CCB alone is most likely caused by other mechanisms.  
7.4 Paper IV 
Plasma noradrenaline was significantly lower after additional treatment with ARB,             
304 ± 29 pg/ml after treatment with losartan 100 mg + amlodipine 5 mg compared to          
373 ± 43 pg/mL after treatment with amlodipine 10 mg (p-value=0.022). HRV, BRS or 
plasma adrenaline did not differ significantly between the two treatment regimens. The 
reduction seen in plasma noradrenaline may indicate a potential beneficial peripheral 
mechanism on the noradrenaline turnover. We think that improvement of insulin sensitivity 
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and possible reduction in diabetes development by blockers of RAS may be related to the 
decreased plasma noradrenaline and potential sympatholytic effects. 
7.5 Paper V 
In the high-risk hypertensive VALUE population, patients with diabetes mellitus at baseline 
had higher cardiac morbidity and mortality than patients without diabetes. Also patients that 
developed diabetes during the average follow-up of 4.2 years of the trial had higher cardiac 
morbidity. This indicates that these patients who develop diabetes during antihypertensive 
treatment have cardiac morbidity intermediate between diabetics and never diabetics, and that 
it is of importance to find these patients at risk of diabetes development and optimise life style 
and medical treatment.  
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8. Discussion 
8.1 Methodological considerations 
8.1.1 Study subjects and methods 
8.1.1.1 The GOAAL study 
The acronym GOAAL was not used in the papers because we did not want to emphasise on a 
special generic drug, but on the ARB drug class as a whole. Patients in the GOAAL study 
were recruited due to being at special risk of developing diabetes mellitus. In a previous study 
from our group we found that open treatment with the ARB losartan for 6 weeks in patients 
with severe hypertension (untreated diastolic blood pressure (BP) 115 mmHg or treated >95 
mmHg) improved insulin sensitivity and reduced plasma noradrenaline significantly132.
However, in a follow-up randomised double-blind placebo-controlled crossover study, 
treatment of mildly hypertensive patients (office BP >140/95 mmHg or home diastolic BP > 
90 mmHg) with losartan for 4 weeks had neutral effect on insulin sensitivity133. Although, not 
an endpoint in the study, the authors found improvement of insulin sensitivity in the most 
insulin-resistant patients133. These results may be due to “regression towards the mean”, 
however we decided to investigate the effect of ARB treatment in patients at special risk of 
being insulin-resistant. Patients with glycaemic disarrangement like IGT or IFG are at risk of 
developing diabetes mellitus. Post-load hyperglycaemia reflects the acute increase in blood 
glucose after a glucose load and peripheral insulin sensitivity, whereas fasting blood glucose 
shows the glucose concentration after an overnight fast and reflects mostly hepatic glucose 
production. Other inclusion criteria in the GOAAL study were obesity and dys-lipidaemia, 
criteria often included in metabolic syndrome and known risk factors for diabetes 
development24.
 We used a crossover design with 8 weeks treatment-periods due to knowing the full 
antihypertensive effect of losartan is evident first after 6-8 weeks133. Since all the patients 
were moderate hypertensives and required antihypertensive medication, a placebo-controlled 
study was not an option. We used a CCB, amlodipine, as the comparator due to also being a 
vasodilator and to investigate if an ARB could have an effect beyond the vasodilating effect 
of a CCB. It would have been better to compare a CCB with ARB alone, but as all the patients 
were hypertensives in need of antihypertensive treatment, we did not find it ethical to take 
them off medication for the “run-in” and “wash-out” periods and the patients were therefore 
treated with open-label amlodipine 5 mg throughout the study. 
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Insulin sensitivity was measured using the hyperinsulinaemic glucose clamp. It’s 
considered to be the “gold standard” due to the direct measurement of the insulin effect to 
promote glucose utilisation60. In the early studies of insulin sensitivity from our group the 
blood sampling arm was warmed with a heating sleeve or cuff in order to arterialise venous 
blood for the estimation of arterial blood glucose (i.e. the stimulus to insulin secretion)133.
This manoeuvre gives higher blood glucose values and may affect the estimated glucose 
disposal, but it may also induce haemodynamic effects like systemic vasodilatation and reflex 
tachycardia that might have an effect on glucose metabolism, so in the latest studies from our 
group we have not used the heating cuff239. There is a lack of consensus regarding the optimal 
length of the glucose clamp, but 120 minutes clamp procedure is often used60, 61. The time to 
insulin action is slowed in obesity and non-insulin dependent diabetes mellitus240, and a 
shorter and less time-consuming clamp examination of our patients with obesity and risk of 
diabetes mellitus development may have influenced the results due to not reaching steady 
state before ending the clamp procedure and was not an option. 
Oral glucose tolerance test was not included in our study in order to minimise the 
strain on the recruited volunteers. If we had included an oral glucose tolerance test, the 
patients had to meet at the hospital on two separate days for each examination and we 
therefore chose to focus on the “gold standard”, the glucose clamp, for examination of insulin 
sensitivity.  
HOMA-IR analysis in a short- term study is questionable, but it has been included for 
the completeness of the results. We measured insulin in pmol/l and have therefore calculated 
HOMA as serum glucose (mmol/L) multiplied by serum insulin (pmol/l) and divided with 
135241, compared to dividing with 22.5 when insulin is measured in mU/L. This means that 
the values of HOMA-IR in our study can be compared with the HOMA-IR used in other 
studies measuring serum insulin in mU/L. 
Adipokines in the GOAAL study was investigated in venous blood samples, and 
possible differences in tissue (adipose and skeletal muscle tissue) in our patients cannot be 
ruled out. 
8.1.1.2 The VALUE trial 
The VALUE trial is a large multicentre trial including patients from more than 30 countries, 
and large trials have advantages and disadvantages. In trials like this there is a trade-off 
between number of variables included and making busy investigators able to cope with the 
registration schemes. National and local differences in investigation and treatment strategies 
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are also challenging. The patients were included according to the presence of predefined 
combinations of cardiovascular risk and disease factors, and this is due to the fact that most 
trials need high-risk patients to get enough endpoints to prove significance, but of course this 
may cause some limitations in the possibility to generalise. 
The primary endpoint in the VALUE trial was cardiac morbidity and mortality. 
However, new-onset diabetes was pre-specified as an endpoint in a study newsletter during 
the trial. The definition of diabetes was changed during the blinded phase of the trial to adhere 
with the WHO 1999 criteria24, and the investigators were encouraged to use the WHO 1999 
criteria when reporting diabetes mellitus and adverse events. We used three different 
databases to investigate new-onset diabetes in the VALUE trial (adverse events, antidiabetic 
drugs and a blood sample at study end). The patient could qualify with one, two or three 
criteria, but could only count once in the final database. By using three different databases the 
results were made more robust, however, in some patients the diagnosis were made on the 
basis of only one single blood sample at study end. On the contrary the baseline diagnosis of 
diabetes may also be on the basis of only one glucose value, and as known from the ELSA 
(European Lacidipine Study on Atherosclerosis) study a substantial proportion (42%) of the 
initial baseline diabetes mellitus diagnosis could no longer be confirmed at study end after 
average 3.8 years using the same criteria242. This indicates the vulnerability in the analysis 
using only one blood sample for the diabetes diagnosis, however this is a trade-off in large 
trials. 
There was a relatively high incidence of new-onset diabetes (3.1% per year) in the 
VALUE trial compared with other hypertension trials like ALPINE (2.3% per year)141,
ALLHAT (2.6% per year)139, CAPPP (1.1% per year)143, LIFE (1.5% per year)144, and 
NORDIL (1.0% per year)243. However, this can be related to different diagnosis criteria of 
new-onset diabetes, using the WHO 1985238 or the more strict WHO 199924 criteria for 
diabetes, and the high-risk population included in the VALUE trial. 
Investigation of cardiac outcomes in the patients with new-onset diabetes mellitus was 
a prespecified analysis in this prospective randomised trial, however, the analyses were by 
nature retrospective and analysed after the trial was ended. We included all clinical events 
during the trial period for the patients in the new-onset diabetes group; also events happened 
before the actual diagnosis of diabetes. This can be discussed, but was done due to knowing 
that the risk of cardiovascular disease is increased long before the clinical diagnosis of 
diabetes35.
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8.1.2 Statistics 
8.1.2.1 The GOAAL study 
Statistical analyses in the GOAAL study were performed using SPSS version for Windows 
(SPSS Inc., Chicago, Illinois, USA). The distribution of each data sample was tested for 
normality, and initial non-normally distributed variables were tested again for normality after 
natural logarithmic transformation. Based on this consideration, either parametric or non-
parametric statistical tests were used. Continuous variables were examined for statistical 
significance using paired sample t-test. Null hypotheses were rejected if the p-values were 
below 0.05. Data were given as mean values and their standard errors (SEM). 
In a crossover study the same group of patients are given both treatment regimens in 
sequence, and randomisation is used to determine the order in which the treatments are 
received. This means that the comparison between the treatments is “within-subjects” rather 
than “between-subjects”, and the sample size needed is smaller244. However, carry-over 
effects may appear with the crossover design meaning that the results obtained during the 
second treatment period are affected by what happened in the first period244. We therefore 
used a wash-out period of 4 weeks between the treatment periods. This may minimise carry-
over effects, but possible carry-over effects must still be considered in the results. One way to 
assess carry-over effects from the initial treatment period to the next is to compare the percent 
changes from baseline to the respective first and second treatment period. However, in our 
study we did not have insulin sensitivity (and most of the other endpoint parameters) at 
baseline. This design was chosen to minimise the stress on the patients and because 
differences in blood pressure must have been considered if baseline values were used, and 
would have made the analyses of baseline variables difficult. The results from baseline or visit 
1 are not homogenous as the patients then were untreated or treated with different anti-
hypertensives. However, baseline variables measured have been included in papers to better 
describe the study-population. 
Nine of the 17 patients who successfully completed two glucose clamp examinations 
were treated with amlodipine in their first crossover period, and GDR on amlodipine 10 mg 
treatment was the same for the patients randomised to this treatment in their first crossover 
period (4.2 ± 0.8 mg/kg/min, n = 9) and those randomised to this in the last crossover period 
(4.2 ± 0.6 mg/kg/min, n = 8). The GDR on losartan 100 mg + amlodipine 5 mg was 4.5 ± 0.4 
mg/kg/min in the patients given the losartan treatment regimen in the first crossover period, 
and 5.2 ± 0.6 mg/kg/min in the patients given the losartan treatment regimen in the second 
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crossover period. This indicates an effect of additional ARB treatment and no carry-over 
effect.  
There may also be a systematic difference between the two treatment periods in a 
crossover design e.g. observations in the second period may be lower (or higher) than those in 
the first period, regardless of treatment244.  No such “period effect” was seen in our study. 
One other disadvantage of the crossover design is that unsuccessful analyses or 
withdrawal, e.g. due to side-effects, exclude the patients from the analyses. This decreases the 
sample size and the statistical power, and unfortunately we lost four patients in the analysis of 
GDR due to technical problems during one of the two clamp procedures. The sample size of 
22 patients was made on calculations of expected difference in insulin sensitivity between the 
two treatment regimens based on previous studies133. And the sample size was not calculated 
based on secondary endpoints like adipokines, inflammatory markers, HRV and BRS. These 
analyses may be vulnerable for type II errors meaning that non-significant results may in fact 
be due to a too small sample size and lack of power, and not due to a true null hypothesis. In 
our analyses of adipokines and inflammatory variables there were consistent results with no 
difference between the treatment regimens (except maybe for adiponectin) so we concluded 
that there was no significant difference in these variables (Paper III). The sample size in our 
study was also comparable to previous studies on adipokines. The lack of significant 
difference in the HRV and BRS analyses may also be due to a type II error as retrospective 
power calculations according to the standard deviations in our HRV analyses estimated that 
we would have needed a sample of 30-200 patients to find significant differences in some of 
the different HRV analyses (Paper IV). 
8.1.2.2 The VALUE trial 
In the VALUE trial Statistical Analysis System (SAS Inc. Cary, North Carolina, USA) was 
used for all statistical analyses, and all tests were 2-sided, and the significance level was set at 
5%. Data are expressed as mean and their standard deviation (SD) for continuous variables 
and categorical variables are presented as frequencies and percent (%).  
Both univariate and multivariate logistic regression models were used to evaluate 
baseline demographic, risk and disease factors, baseline laboratory variables and prior 
antihypertensive medication that significantly predicted diabetes mellitus development (Paper 
I). Twenty-five potential baseline predictors of new-onset diabetes mellitus were identified in 
the trial database, and univariate logistic regression analyses were used to identity predictors 
with a significant p-value of below 0.05 and to calculate odds ratios for diabetes development. 
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Multivariate stepwise logistic regression analyses were used to further define significant 
baseline predictors in four different models. A stricter p-value was used in the multivariate 
analyses (p-value <0.001) than in the univariate analyses to get a simple model with the most 
important predictors of diabetes development. The results are presented as Chi-Square (Ȥ²)
with correspondant odds ratios. An odds ratio > 1 indicates an increased risk of diabetes 
mellitus development, while an odds ratio <1.0 indicates reduced risk. We used the odds 
ratios from the final multivariate model and compared them to the univariate model to make 
sure that the results were consistent.  For example the odds ratio was 2.179 for baseline 
glucose in the univariate analysis vs. 2.106 in the final multivariate model, and this indicates 
consistency.   
To provide additional validation of the results from the multivariate stepwise model 
building, the patients with new-onset diabetes mellitus and those without were randomly split 
in two; a learning sample of 40% (3999) and a validation sample of 60% (5996) of the 
patients. The model building using multivariate stepwise logistic regression was then repeated 
on the learning sample with a significance criterion of p-value <0.05, and the identified model 
was then checked on the validation sample with a criterion of p-value <0.05.  
A Cox regression model for endpoints was used when analysing cardiac endpoints in 
the patients with baseline diabetes, new-onset diabetes and without diabetes (Paper V). The 
VALUE trial was an event driven trial, and patients in the trial have different numbers of 
years of follow-up. We were missing the exact dates for diagnosing new-onset diabetes (e.g. 
debut of adverse events or anti-diabetic drugs were reported without dates in 87 patients or 
6.7% of the total 1298 patients with new-onset diabetes) and in the database these patients 
with new-onset diabetes are assigned to have new-onset diabetes at randomisation date.  
In the primary analyses of cardiovascular endpoints we adjusted for pre-defined 
covariates (age, diabetes status, LVH, CHD and randomised study treatment). However, other 
known covariates were included in a secondary Cox regression model (baseline and in trial 
use of aspirin, statins, beta-blockers, diuretics, diuretics and beta-blocker combination, blood 
pressure, heart rate and sex). Pair-wise comparison between patients without diabetes and 
patients with diabetes at baseline as well as patients without diabetes and patients with new-
onset diabetes were performed with corresponding HRs, and the patients without diabetes 
mellitus both at baseline and at the end of the trial (never diabetes) were used as comparator. 
Event rates over time by the three groups were also presented as Kaplan-Meier curves.   
Given the overall large number of patients studied in the VALUE trial some results, 
although statistically significant, may not be clinically relevant. There may also be type I 
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errors meaning that the null hypothesis is rejected, i.e. a significant test result is demonstrated, 
when the null hypothesis in fact is true. However, as the results are consistent throughout 
different models of univariate and multivariate logistic regression analyses and after 
additional validation, the results are most likely to be reliable and robust (Paper I). As always, 
one should be cautious in interpreting results from regression analysis, which only 
demonstrates an association between the dependent and independent variables and does not 
necessarily imply a causal effect. 
8.2 General discussion 
8.2.1 Detection of hypertensives at high-risk for diabetes development 
Higher-than-optimum blood glucose is a leading cause of cardiovascular morbidity and 
mortality worldwide245, and it is of great importance to detect patients at risk of developing 
diabetes mellitus, as many remain unaware of their disease, and complications may develop 
before the actual diagnosis35, 43. Instead of a general screening for diabetes mellitus with blood 
glucose measurement of all patients, identifying subgroups with special risk may be cost-
efficient. In fact a survey from Great Britain has shown that screening for diabetes mellitus in 
general practice by measuring fasting blood glucose has a very low yield in low risk 
populations246. However, screening in high-risk populations may be cost-effective. Patients 
with assumed metabolic abnormalities, including those who are obese, hypertensive or have 
prevalent cardiovascular disease or a family history of diabetes may be of interest for further 
testing and different risk scores have been developed for these purposes e.g. Diabetes Risk 
Score247 (or FINDRISC248), Diabetes Risk Test249.
 In the VALUE trial including high risk hypertensive patients, investigation of 25 
baseline predictors showed that six easily accessible baseline predictors (glucose, BMI, non-
Caucasian race, low age, heart rate and history of CHD) were significant predictors of new-
onset diabetes mellitus in a multivariate model including all patients and excluding 
randomised treatment (Paper I). The randomised study treatment with amlodipine or valsartan 
was not included in the final chosen model due to making the model more general and better 
to use in other settings. 
Glucose at baseline was by far the most important risk factor for new-onset diabetes 
mellitus in all analyses and models used in our study, and this was not unexpectedly due to 
previous results33, 34. BMI was the next most important predictor of new-onset diabetes 
mellitus in all our analyses. Obesity and abdominal fat distribution are well-known risk 
factors for type 2 diabetes mellitus. The natural history of diabetes mellitus development may 
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be exaggerated by obesity because elevated levels of free fatty acids may both directly impair 
peripheral glucose utilisation and increase hepatic gluconeogenesis250, and indirectly affect 
hepatic auto-regulation through altering hypothalamic sensing251. Altered secretion of 
adipokines from adipocytes or macrophages in fat tissue may be another mechanism involved 
in the dys-regulation between fatty tissue and glucose metabolism. Waist circumference may 
predict diabetes mellitus better than BMI, as BMI does not differ between fat and muscles and 
may overestimate obesity especially in young men37. However, BMI was the measurement of 
obesity in the VALUE trial and was a highly significant predictor of new-onset diabetes 
mellitus in both univariate and multivariate analyses. 
The prevalence of diabetes mellitus is increasing with age252, but in our VALUE trial 
population increasing age at baseline was associated with a lower risk of developing diabetes 
mellitus during the trial-period. We assume this is caused by selection, and the inclusion 
criteria inasmuch as only high-risk hypertensive patients above the age of 50 could qualify for 
the study, i.e. high-risk elderly hypertensives may by being survivors of long-standing 
hypertension without diabetes mellitus development, gradually lose the metabolic ability of 
the disease, and these elderly hypertensives may survive because they do not have the same 
underlying risk of metabolic disease as the younger hypertensives. Partially, this was also 
seen in the LIFE (Losartan Intervention For Endpoint) study144, 253 and in the recently 
published results from the ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial-
Blood Pressure Lowering Arm) study254. Epidemiological data included in the DECODE 
(Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe) study have 
shown that fasting and post-load glucose values do not identify the same patients and are 
influenced differently by the aging process252. IFG prevalence tends to plateau in middle age, 
whereas the prevalence of IGT continues to increase also into older age25, 252. In our study we 
mainly defined diabetes mellitus according to fasting glucose values, which may be another 
explanation for the age-findings in VALUE and other trials144, 253, 254.
There are known differences in diabetic risk between races, and African Americans are 
known to have an elevated risk of diabetes mellitus compared with Caucasian29. In the 
VALUE trial most of the patients were Caucasian (91.1%), and patients that were non-
Caucasian (3.2% black, 3.4% oriental, 2.3% other races) developed more diabetes mellitus. 
Baseline heart rate was a significant predictor of new-onset diabetes mellitus in all our 
analyses except the multivariate analysis in model 4 (patients treated with amlodipine). These 
results suggest a possible sympathetic drive as an underlying pathophysiological mechanism 
for diabetes development, and a possible sympathetic effect of amlodipine may have 
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diminished the effect of heart rate as a predictor in the amlodipine-treated patients89, 195. A 
history of CHD was a significant predictor in both the univariate and multivariate model 
including all patients, but a previous history of cerebrovascular disease or peripheral arterial 
occlusive disease were not significant predictors in any of the analyses. This may be due to 
fewer patients included with these diseases or a different relationship between different risk 
factors and different cardiovascular diseases. Randomised study treatment was a highly 
significant predictor of new-onset diabetes mellitus, and treatment with the ARB valsartan 
reduced new-onset diabetes mellitus by an absolute 3% and a relative 23% compared with 
amlodipine in the VALUE trial137. However, we decided not to include study treatment in our 
final model due to making the model more general.  
In the LIFE study, 562 of the 7998 non-diabetic hypertensive patients with ECG-
documented LVH developed diabetes mellitus during the average follow-up of 4.8 years144.
LIFE was the first study that made use of the ability to analyse the appearance of new-onset 
diabetes mellitus in patients with different levels of risk and significant predictors of diabetes 
development from multivariate analyses were non-fasting glucose, BMI, HDL-cholesterol, 
systolic BP and prior use of antihypertensive drugs144. HDL-cholesterol was not studied as a 
predictor in the VALUE trial, and systolic BP was not a significant predictor in our univariate 
analyses. This is possibly due to the roll-over design in the VALUE trial which did not 
include a wash-out period without antihypertensive treatment, and thus lack “true” baseline 
BP values234, 235.
The recently published results from the ASCOT-BPLA showed that 1366 of the 14120 
patients "at risk" of developing diabetes subsequently developed diabetes during the median 
follow-up of 5.5 years254.  Increasing fasting plasma glucose, BMI, serum triglyceride and 
systolic BP were associated with diabetes development, while randomised treatment with the 
CCB amlodipine ± ACEI perindopril, high HDL-cholesterol, alcohol use and age were found 
to be protective factors against diabetes development254.  The most powerful predictor of new-
onset diabetes mellitus in the ASCOT-BPLA was as in the VALUE trial, glucose level which 
increased the risk of diabetes development 5.8-times (5.23-6.43) for each mmol/L rise of 
glucose above 5 mmol/L254.
In the CAPPP (Captopril Prevention Project) study glucose, BMI, haemoglobin, age, 
interaction between systolic BP and newly diagnosed hypertension, total-cholesterol and prior 
antihypertensive treatment were significant risk factors in a multivariate analysis143, 255. The 
CAPPP study included low-risk patients from only Sweden and Finland indicating a less 
general population than the VALUE trial. 
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In a 28-year follow-up of 754 hypertensive patients from Sweden, 148 patients 
(20.4%) developed diabetes and BMI, triglycerides and treatment with beta-blockers were 
independently and positively related to the diabetes development in a multivariate Cox 
regression analysis95.
Information about family history of diabetes mellitus and physical activity, diet, 
alcohol use, gestational diabetes, waist-hip-ratio, insulin, triglyceride and HDL-cholesterol 
levels, all well-known and strong risk factors for diabetes mellitus development, are not 
included in the VALUE database. On the other hand the baseline predictors found in our 
study can easily be evaluated and used by physicians in treating patients in daily practice. The 
VALUE trial included mainly Caucasian patients (91.1%), and this limits the possibility to 
generalise. The age- and gender-algorithm used for recruitment also limits the precision of 
using these two variables as completely reliable predictors. The investigators were urged to 
use the WHO 1999 definition of diabetes mellitus24, but we can not rule out some 
misclassification by the investigators. Large-scale randomised clinical trials are not designed 
to investigate pathophysiological issues and can only suggest possible mechanisms behind 
development of diabetes mellitus, but may generate hypothesis to be investigated in other 
studies. The proper validation of results like these is either by evaluating the risk factors in a 
prospective non-selected population based cohort or applying the results on other similar trial 
data (which is expensive and complicated from an administrative point of view due to 
different investigators and different pharmaceutical companies sponsoring other large trials), 
or to split the data into two halves using one for the model and the other for validation, which 
we have done in this context.    
However, the predictors for diabetes development found in the VALUE trial 
population might help in identifying patients at risk, and within the context of limited health 
care resources it is sensible to focus initially on those at the highest risk of developing 
diabetes, and these patients should receive the most effective investigations and interventions 
available. 
8.2.2 Possible mechanisms for improved insulin sensitivity and reduction of new-onset 
diabetes mellitus seen with blockers of RAS 
In the GOAAL study we found that in hypertensive patients treated with additional ARB 
losartan significantly improved insulin sensitivity as assessed by the glucose clamp technique, 
and there was also a trend towards lower values of HOMA-IR (Paper II). Insulin-mediated 
glucose uptake during the hyperinsulinaemic isoglycaemic glucose clamp occurs mainly in 
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skeletal muscle and is dependent on muscular blood flow60. Thus, an increase in blood flow 
induced by vasodilating drugs would be expected to increase glucose uptake. The observed 
effect in the GOAAL study was beyond the vascular effects and blood pressure reduction 
achieved by maximal calcium channel blockade with amlodipine as the blood pressure 
reduction was similar during the two treatment periods. This indicates a possible non-
haemodynamic effect of the AT1-receptor blocker explaining the improvement in insulin 
sensitivity. 
One hypothesis is that blockade of RAS may reduce the risk of diabetes development 
by stimulating proliferation and differentiation of pre-adipocytes into small insulin-sensitive 
adipocytes146. This prevents ectopic fat storage e.g. in liver, skeletal muscle, and pancreas, 
which is associated with insulin resistance. Skeletal muscle is responsible for most of the 
insulin stimulated glucose disposal and takes up significant quantities of plasma fatty acids for 
energy production (oxidation) or for storage in intracellular lipids57. Thus an elevation in 
circulating fatty acids in obese humans results in increased uptake and excess deposition of 
lipids within the muscle cell and aggravates insulin resistance. Reduced plasma adiponectin is 
strongly and independently associated with insulin resistance and type 2 diabetes 
development57, 148. We also found that adiponectin concentrations in our patients correlated 
well with insulin sensitivity as measured with the hyperinsulinaemic isoglycaemic glucose 
clamp, and this was the only investigated adipokine with a significant correlation with insulin 
sensitivity after both treatment periods. However, no significant differences were found in 
adipokines between the two treatment regimens, and the reason may be due to the limited 
number of patients included in our study and a possible type II error. We also compared two 
active treatment regimens in our study, and this may have diminished a possible effect of 
RAS-blockade. To our knowledge the effect on adipokines between CCB and ARBs has not 
previously been investigated in a crossover design.
Subclinical chronic low-grade inflammation has been suggested to have a role in 
insulin resistance and development of type 2 diabetes mellitus, and correlation between pro-
inflammatory biomarkers (CRP, IL-6 and TNF-Į) and glucose dys-regulation, obesity and 
atherosclerosis has been shown256. No significant difference was seen in these parameters in 
the GOAAL study, but this may be due to a too small sample size to detect these possible 
differences during only 8 weeks treatment. Reduced fibrinolytic activity has also been 
associated with abdominal obesity and insulin resistance257, but no significant difference in 
the PAI-1 activity was seen between our two treatment regimens.  
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We observed a consistent trend towards lower viscosity as vasodilatory treatment was 
intensified (baseline-amlodipine 5 mg-amlodipine 10 mg- losartan 100 mg + amlodipine 5 
mg). Previous studies from our group have shown that WBV is negatively related to insulin 
sensitivity231, but no significant difference in WBV and correlation with the improved insulin 
sensitivity was found between the two treatment regimens in the GOAAL study. The 
difference in WBV found from baseline and open-label amlodipine 5 mg treatment to 
treatment with both amlodipine 10 mg and losartan 100 mg + amlodipine 5 mg is probably 
related to the reduction in blood pressure, but also a significant reduction in haemoglobin 
level seen from baseline and open-label treatment to the treatment regimen with losartan may 
explain the reduced viscosity.  
 The relationship between glucose intolerance and hypokalaemia has been known for 
decades and was originally proposed by Conn to explain the apparent diabetic state found in 
primary aldosteronism103. The insulin secretory response of pancreatic ȕ-cells to glucose is 
known to be decreased during hypokalaemia258, and prevention of hypokalaemia after 
treatment with ACEIs or ARBs may explain the improvement of insulin sensitivity and the 
lower risk of diabetes development seen with these drugs. However, no significant difference 
in measured potassium was seen in the GOAAL study after additional ARB treatment, but this 
may of course again be related to power of the study and potential type II error.
 The difference in insulin sensitivity seen in our study may be due to different effects 
on the sympathetic-parasympathetic balance by our two treatment regimens. Our findings of 
significant lower venous plasma noradrenaline levels after additional ARB treatment with 
losartan support this assumption. According to the hypothesis of Julius et al.68, enhanced 
sympathetic activity is the primary factor to be associated with hypertension, insulin 
resistance and possibly obesity. Sympathetic stimulation can cause insulin resistance, and 
insulin resistance can reciprocate sympathetic stimulation, and a vicious cycle evolves in 
which the components reinforce each other68. Enhanced sympathetic tone can cause 
peripheral insulin resistance by ȕ-adrenergic stimulation259, by conversion to more fast-twitch 
insulin-resistant muscle fibres260, by decreased capillary density198 and/or by Į-adrenergic 
vasoconstriction89, 261-263. As treatment with the CCB amlodipine has shown to increase 
sympathetic activity in some previous studies112, 204, 264-267 and blockers of RAS may reduce 
sympathetic activation9, an effect on the SNS may be a plausible explanation for our results. 
However, no significant differences were seen in HRV, BRS or plasma adrenaline. Other 
studies have also shown that an increase in noradrenaline concentration with amlodipine is not 
associated with an increase in adrenaline levels265, suggesting that there is a clear dissociation 
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between the activation of sympathetic nerves and of the adrenal medulla. Although, no 
significant differences in HRV and BRS after treatment with an ARB in our study-population; 
there was a trend towards higher HF (representing vagal tone), and a lower LF (representing 
sympathetic with vagal tone), and therefore a lower LF/HF spectral power ratio measured, 
suggesting a shift in the sympatovagal balance towards less sympathetic drive after treatment 
with an ARB. It has been suggested that abnormalities in cardiac parasympathetic regulation 
precede impairment of blood vessel sympathetic control268, and as we expected differences 
primarily in the SNS this may be one explanation why we did not find an effect on HRV and 
BRS in a short time study like this. It is also possible that a potential effect of the ARB 
treatment was attenuated by the sympathetic activation induced by the open label CCB 
amlodipine.  
There are other possible mechanisms for the improved insulin sensitivity and the 
reduced new-onset diabetes mellitus seen with blockers of RAS, which are not investigated in 
our study. Endothelial dysfunction and microvascular changes may affect insulin sensitivity, 
and endothelial dysfunction is common in patients with essential hypertension269. RAS 
blockade with ACEIs or ARBs has improved endothelial dysfunction and microcirculation in 
hypertensives253, 270, 271 and may be one other reason for the reduction seen in diabetes 
development after treatment with these drugs. Reduction of angiotensin II’s potential toxic 
effects on pancreatic islet morphology and blood supply is another alternative mechanism272, 
273. It has also been reported that the ARB telmisartan has partial PPAR-Ȗ agonistic effects in 
concentrations achievable with oral doses recommended for treatment with hypertension55, 172.
This suggests an insulin-sensitising effect of at least telmisartan like the antidiabetic drugs 
thiazolidinediones. The ARB losartan used in the GOAAL study has two active metabolites; 
EXP3174 is the main antihypertensive metabolite and EXP3179 has a more unknown role274.
It has recently been shown that the metabolite EXP3179 induce partial PPAR-Ȗ activation in 
vitro, which may explain the beneficial metabolic effects of losartan observed274. However, to 
my knowledge no clinical studies have reported PPAR-Ȗ effects after losartan treatment in 
recommended antihypertensive doses172, 274. Possible mechanisms for this insulin-sensitising 
ability by ARBs may be through augment in the number of the glucose transporter GLUT-4 
and energy metabolism in adipose tissue and peripheral tissue275, 276. These intracellular 
mechanisms including cell culturing have not been investigated in the GOAAL study. A 
possible insulin-sensitising effect of ACEIs mediated through increased bradykinin levels has 
also been suggested277, however this may not be the sole explanation of the beneficial effect 
of RAS blockers as ARBs (without bradykinin-effects) also have shown effects on insulin 
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sensitivity and reduction in diabetes development. Recently in a systematic review by 
Matchar et al.278, the authors compared the effectiveness of ACEIs and ARBs in treating 
hypertension and concluded that ACEIs and ARBs, with exception of cough, do not have 
clinically meaningful differences in benefits or harms including diabetes development. Figure 
5 summarises some of the possible mechanisms for reduction in new-onset diabetes mellitus 
seen with RAS blockers. The anti-diabetic mechanism is probably complex, but based on our 
results a possible effect on the SNS is our main hypothesis. 
Figure 5: Possible mechanisms for preventing diabetes mellitus with ARBs  
(Modified from Aksnes TA et al.”The role of ARBs in the management of hypertension” One 
Way Publishing, 2006:41) 
Adipocyte
differentiation
Inappropriate
gluconeogenesis
Vasodilatation
Prevent 
hypokalemia
K+
Improved peripheral
insulin sensitivity
+
+
+
+
+
–
+
+
Sympathetic
nervous system
– ARB
NA
Preserved 
pancreatic insulin 
secretory response
GLUT 4
8.2.3 Diabetes development in hypertension - does it matter? 
Quantification of the total health effects of diabetes mellitus and diabetes development is 
complicated. Diabetic patients often have and die of other diseases, especially cardiovascular 
diseases, and this may not be registered in e.g. epidemiological studies using only mortality 
rates. Patients with diabetes mellitus also often have other risk factors, which complicate the 
picture. The risk of cardiovascular morbidity and mortality also increases continuously with 
increasing blood glucose concentration and a diagnostic threshold of diabetes may be looked 
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upon as arbitrary279, 280. It has been suggested that treatment-related new-onset diabetes 
mellitus may not have the same adverse prognostic effect as “spontaneously” occurring 
diabetes. This view has been based on the apparent “innocent” nature of new-onset diabetes as 
there has not been seen any strong association between the incidence of new-onset diabetes 
and an excess risk of hard endpoints in trials92, 139, 281. However, cardiovascular complications 
due to new-onset diabetes may first develop long after the follow-up period, and these 
randomised clinical trials have not been designed for these purposes35, 40. In our results, 
despite the short time of observation, we found a significantly increased risk of cardiac 
morbidity in patients with new-onset diabetes mellitus compared to patients without diabetes 
during the average 4.2-years of follow-up in our pre-specified analyses282 (Paper V). Patients 
with diabetes at baseline had as expected the highest cardiac morbidity and mortality rates, 
but the patients with new-onset diabetes also had increased cardiac morbidity defined as 
myocardial infarction and heart failure, compared to patients without diabetes mellitus.  
 There was especially an increase in heart failure in the patients with diabetes compared 
to the patients without diabetes, both baseline and new-onset diabetes. Possible mechanisms 
may be more coronary heart disease and diabetic microangiopathy or cardiomyopathy in these 
patients. Another hypothesis may be that this is related to more atrial fibrillation in this high-
risk patient group282. Also increased glucose levels below the threshold of the diabetes 
diagnosis may increase the risk of heart failure. For example in the 
ONTARGET/TRANSCEND trials a 1 mmol/L higher fasting plasma glucose predicted a 
1.10-fold-increased risk of hospitalisation for congestive heart failure (1.09-1.12, p-
value<0.0001)283. It has been hypothesised that prediabetic individuals might have an 
atherogenic pattern of risk factors even before the onset of clinical diabetes, thereby 
explaining the relative lack of an association of macrovascular complications with either 
glycaemic severity or disease duration43. However, the concept of “prediabetic” is also 
controversial in itself as it is only provable in retrospective analyses284.
 There was an increased event rate of stroke in the patients with diabetes at baseline, 
but no difference in stroke was found between patients with new-onset diabetes and patients 
without diabetes in the VALUE trial (Paper V). In the 28-year Swedish follow-up study of 
hypertensives, the risk of stroke was significantly higher in patients with diabetes at entry, 
whereas this was not the case in patients who developed diabetes mellitus during the first 10 
years of follow-up95. However, in multivariate regression analyses the development of 
diabetes mellitus during the whole study was significantly associated with an increased 
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relative risk of stroke of 67% (1.1-2.6, p-value<0.05), indicating it may take time before the 
increased risk of stroke is showing. 
 Somewhat unexpected we found decreased over-all and cardiac mortality in the 
patients with new-onset diabetes compared to the patients without diabetes (Paper V). This is 
probably due to statistical issues as it is difficult to assess mortality in the patient group with 
new-onset diabetes mellitus in our study because by definition fatal event in this group could 
only occur after the time of the diabetes diagnosis. This makes it difficult to compare 
mortality rate with the other two groups (baseline diabetics and never diabetics), where deaths 
could be counted throughout the trial. This short duration of follow-up and the limited number 
of events in the new-onset diabetes population (e.g. only 20 cardiac deaths registered in the 
new-onset diabetes group) makes the results vulnerable for chance findings. On the other 
hand when looking at these observational data, more aggressive treatment was reserved by the 
VALUE investigators to the patients with new-onset diabetes (more aspirin, beta-blockers, 
diuretics and statins), and this intensive treatment of cardiovascular risk factors may also has 
reduced mortality.  
Long-term observational studies have shown higher incidence of cardiovascular 
complication in patients having developed diabetes during antihypertensive treatment 
(predominantly with diuretics and/or beta-blockers)32, 93, 95, 285, 286. However, in the 14-year 
follow up of the SHEP-study newly occurring diabetes among actively treated patients (the 
diuretic chlorthalidone plus eventually the beta-blocker atenolol) was not associated with 
increased mortality98. These long-term results were retrospective, achieved in elderly patients 
and the authors used an administrative database to adjudicate vital status and cause of death, 
which may diminish the impact of the results. The SHEP-study was also placebo-controlled 
and the results can also be interpreted as a favourable effect of better blood pressure control 
per se and indicates that any treatment is better than no treatment or control, even when a non-
metabolically optimal therapy is used. In a post-hoc analysis from the ALLHAT study a 
significant increased HR of 1.64 (1.15-2.33) for coronary heart disease was found in patients 
with incident diabetes, but no significant effects on mortality and other endpoints were 
found97. Potential adverse metabolic effects of diuretics and beta-blockers may partly offset 
the beneficial effects of blood pressure reduction on overall cardiovascular risk reduction. To 
ensure maximal cardiovascular protection to hypertensive patients, it seems essential to 
clarify the cardiovascular risk associated with new-onset diabetes mellitus as done in the 
VALUE trial.  
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The VALUE trial has some limitations when evaluating the impact of new-onset 
diabetes. All the patients are hypertensives with a relatively high cardiovascular risk, and the 
patients were of mainly Caucasian origin. This limits the possibility to generalise and caution 
is needed when extrapolating from our results into other ethnic groups. The mortality data 
must be evaluated with caution as we have included all clinical events during the trial period 
for the patients in the pre-specified new-onset diabetes group; also events happened before the 
actual diagnosis of new-onset diabetes. This was done due to knowing that the risk of 
cardiovascular disease is increased long before the clinical diagnosis of diabetes35.
8.3 Future perspectives 
In view of the predicted increase in the number of diabetic patients during the coming 
decades287, it is of great importance from both a medical and an economical perspective to 
reduce the healthcare burden with focus on prevention, early detection and treatment of both 
the glycaemia and co-morbidities. Many patients with type 2 diabetes mellitus are unknown 
of their risk, and their diabetes diagnosis. Blood glucose can rise to diabetic levels with little 
or no symptoms, and the hyperglycaemia may already at the time of the diabetes diagnosis 
have made great microvascular and macrovascular damage. Hypertensive patients have a 
special risk of diabetes development, and must be treated as high-risk patients. In the context 
of clinical trials the development of diabetes mellitus is often treated as a yes-no variable, 
defined by which side of the glucose diagnostic threshold each subject ends up. However, the 
important task is not only to provide that fewer patients are “crossing the line” into diabetes, 
but to find methods to slowing the rate of the failing pancreatic ȕ-cell and the atherogenetic 
process in high-risk patients. Lifestyle changes with a combination of appropriate diet, 
exercise and abstinence from smoking could substantially lower the risk of both hypertension 
and diabetes development36, 51, 52, 288. Good blood pressure control and optimising other 
cardiovascular risk factors may also reduce the total risk of the patients. Patients with 
hypertension have a high total cardiovascular risk, and it’s of importance to prevent 
development of diabetes and the accelerated risk of atherosclerosis. Avoidance of medication 
that could cause weight gain, impair weight loss and/or impair insulin sensitivity or glucose 
tolerance may be important in high-risk patients. RAS blockers have shown promising results 
in preventing or at least postponing the diabetes development, and may improve glycaemic 
control and insulin resistance. However, more research is needed to determine the effect and 
possible mechanisms.
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9. Conclusions 
The main conclusions in the present work can be summarised as follows: 
• Easily accessible predictors can identify hypertensive patients at risk of developing 
type 2 diabetes mellitus. Blood glucose and BMI are the most important predictors. 
• Antihypertensive treatment with additional AT1-receptor blockade can improve 
insulin sensitivity compared to treatment with CCBs in patients with hypertension and 
other cardiovascular risk factors. 
• No significant differences were found in adipokines, inflammatory variables and 
whole blood viscosity after additional treatment of hypertensive patients with AT-1 
receptor blockade compared to treatment with CCB alone. 
• One possible mechanism for the improved insulin sensitivity by AT1-receptor 
blockade may be effects on the sympathetic nervous system. 
• High risk hypertensive patients who developed diabetes mellitus had increased cardiac 
morbidity – increased risk of myocardial infarction and heart failure - compared with 
patients that did not develop diabetes mellitus. 
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